Target enrichment

By using DNA adaptor attachment and nick translation polymerase technology in low-input samples, combining glycosylase and endonuclease, efficient enrichment and amplification of the target sequence is achieved, solving the efficiency in the prior art Low problems reduce costs and increase sequencing depth.

CN119095979APending Publication Date: 2024-12-06NEW ENGLAND BIOLABS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033525.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-09
Filing Date
2023-03-08
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively enrich the target sequences in low-input samples, especially cell-free DNA and DNA isolated in tissue sections. The enrichment method is inefficient, difficult to reduce costs and improve sequencing depth.

Method used

The fusion product is formed by attaching the DNA adaptor to the 5' end of the double-stranded polynucleotide fragment, and the target sequence is carried out using niche translation polymerase and linear amplification technology, combining glycosylase and endonuclease. Enrichment and amplification, and finally enrichment and capture using affinity domain.

Benefits of technology

It realizes efficient enrichment of target sequences in low-input samples, reduces sequencing costs, improves sequencing depth, avoids deviations and polymerase errors introduced during PCR amplification, and improves the accuracy of sequencing results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095979A_ABST
    Figure CN119095979A_ABST
Patent Text Reader

Abstract

The present disclosure relates, according to some embodiments, to methods and compositions for preparing a library of polynucleotides enriched with respect to a target sequence from a source material (e.g., a sample comprising or constituting a biological fluid, tissue, and / or sample). The methods and compositions can provide efficient enrichment of targeted polynucleotides. Enrichment may include increasing the relative abundance of the target from the source material (which may be present at a low abundance) and the generated library (which may be present at a higher abundance). In some embodiments, the methods include attachment (e.g., ligation, linkage, or otherwise fusion) of adapters to fragments of interest, nick translation, amplification (e.g., linear amplification), and target sequence selection using, for example, affinity tags.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of provisional application serial number 63 / 318,194 filed on March 9, 2022, the entire contents of which are incorporated herein by reference.

[0003] Sequence Listing Statement

[0004] The present disclosure includes a sequence listing submitted electronically in .xml format, with the file name "DG-004-PCT.xml", created on March 1, 2023, and with a size of 15.6KB. The entire contents of this sequence listing are incorporated herein by reference. Background Art

[0005] Next generation sequencing (NGS) has become a major tool for genomic research, providing a powerful method for studying DNA samples. NGS-based methods for analyzing genomic variations are currently being vigorously developed. As part of this work, several methods have been developed to enrich specific target sequences (e.g., subregions of the genome), thereby reducing costs and labor and improving results. Target enrichment can be helpful when only part of the genome needs to be enriched / analyzed, such as the "exome" (i.e., all transcribed sequences) or a smaller set of genes or genomic regions involved in a specific disease or pathway. For example, target enrichment can be used to select DNA for a cancer gene set prior to sequence analysis. In theory, selective recovery of target sequences should reduce costs and increase sequencing depth compared to whole genome sequencing.

[0006] Performing targeted enrichment on low-input samples can be challenging, not only because of the limited amount of DNA in the sample, but also because of the inefficiencies of the enrichment methods themselves. Therefore, there remains a need for new methods for targeted enrichment, particularly methods that can be used on low-input samples such as cell-free DNA (cfDNA) and DNA that has been isolated from tissue sections. Summary of the invention

[0007] The present disclosure provides methods for enriching polynucleotides containing a sequence of interest ("target sequence") in a polynucleotide composition. In some embodiments, the polynucleotide composition may include genomic polynucleotides, cellular polynucleotides, organelle polynucleotides, cell-free polynucleotides, or other polynucleotides (e.g., DNA and / or RNA), and the polynucleotides are fragmented, for example, to form a population of fragments having at least some (optionally, all) sizes within a desired fragment size range. The population of fragments may include one or more fragments having a target sequence. According to some embodiments, the method may include attaching (e.g., connecting, joining, or otherwise fusing) a DNA adapter to the 5' end of a double-stranded polynucleotide fragment in a population of double-stranded polynucleotide fragments from a sample, wherein the DNA adapter includes a bottom strand and a top strand, and forms a fusion product. The adapter top strand may include, from 5' to 3': a sequence of at least 8 nucleotides complementary to a linear amplification annealing site; optionally, a sample tag; optionally, a unique molecule identifier (UMI); and a sequence complementary to the adapter bottom strand. For example, where the upper strand of the adapter includes an optional sample tag and / or an optional UMI, the upper strand can be longer than the lower strand of the adapter. The lower strand of the adapter can include a non-extendable 3' end (e.g., an end including an inverted deoxythymidine). The lower strand of the adapter can not include (can exclude) a 5' phosphate, a sample tag, a UMI, and / or a linear amplification annealing site. In some embodiments, the fusion product can include the 3' end of the upper strand of the adapter fused to the 5' end of the polynucleotide fragment and a nick including the unfused 5' end of the lower strand of the adapter and the 3' end of the polynucleotide fragment.

[0008] In some embodiments, a method may include attaching (e.g., connecting, linking, or otherwise fusing) a DNA adapter to the 5' end of a double-stranded polynucleotide fragment in a population of double-stranded polynucleotide fragments from a sample, wherein the DNA adapter comprises an upper strand and optionally a lower strand, and forms a fusion product. The single-stranded adapter may be attached to the double-stranded fragment using, for example, a single-stranded DNA ligase. The adapter upper strand may include, from 5' to 3': a sequence of at least 8 nucleotides complementary to a linear amplification annealing site; optionally, a sample tag; optionally, a unique molecular identifier (UMI); and optionally a sequence complementary to the adapter lower strand. In the case where the upper strand includes a UMI, it may be desirable to include an optional lower strand (e.g., in order to reduce or prevent UMI jumping). In some embodiments, the adapter upper strand may lack a UMI, and the DNA adapter may lack a lower strand. For example, in the case where an optional sample tag and / or an optional UMI are included in the upper strand, the adapter upper strand may be longer than the adapter lower strand. The adapter lower strand may include a non-extendable 3' end (e.g., an end including an inverted deoxythymidine). The adapter lower strand may not include (may exclude) a 5' phosphate, a sample tag, a UMI, and / or a linear amplification annealing site. In some embodiments, a fusion product may include the 3' end of the adapter upper strand fused to the 5' end of the polynucleotide fragment and a nick including the unfused 5' end of the adapter lower strand and the 3' end of the polynucleotide fragment.

[0009] According to some embodiments, the method may further include contacting the fusion product with a nick translation polymerase for templated addition of nucleotides to the 3' end of the polynucleotide fragment to form a nick translation product comprising a 3' extension of the polynucleotide fragment, the extension being complementary to the upper strand of the adapter. The method may further include contacting the nick translation product with a primer having a sequence complementary to the linear amplification annealing site and a polymerase to produce an amplified (e.g., linear amplification) nick translation product. The amplified (e.g., linear amplification) nick translation product may include, for example, in the 5' to 3' direction: a sequence complementary to the linear amplification annealing site; optionally, a sequence of a sample tag; optionally, a sequence of a UMI; a sequence of a portion of the upper strand of the adapter; a sequence of one of the polynucleotide fragments; and optionally, a sequence complementary to a portion of the upper strand of the adapter (e.g., 1-25 nucleotides).

[0010] According to some embodiments, the method can further include, prior to or concurrently with amplification (e.g., linear amplification), contacting the nick translation product with a glycosylase and an endonuclease (e.g., sequentially, together as separate enzymes, or as a fusion protein), wherein the adaptor upper strand template further comprises one or more modified nucleotides, wherein the one or more modified nucleotides are optionally deoxyuridine, the glycosylase is optionally uracil-DNA glycosylase (UDG), and the endonuclease is optionally endonuclease VIII. Nick translation can be expected to displace the adaptor lower strand, and such displaced adaptor lower strand can be expected to be lost by subsequent steps, for example, without any overt action. However, in some embodiments, the method can include removing the adapter lower strand of the adapter template (after nick translation) by cleaving the adapter lower strand with a reagent comprising a glycosylase and an endonuclease, wherein the adapter lower strand comprises one or more modified nucleotides, wherein the one or more modified nucleotides are optionally deoxyuridine, the glycosylase is optionally uracil-DNA glycosylase (UDG), and the endonuclease is optionally endonuclease VIII.

[0011] According to some embodiments, the method may further include contacting the nick translation product of the linear amplification with a target-specific oligonucleotide attached to an affinity domain (e.g., biotin) to form a target complex comprising a polynucleotide fragment having a target sequence, a target-specific oligonucleotide, and an affinity domain, wherein the target sequence hybridizes with the target-specific oligonucleotide. In some embodiments, the method may include binding the target complex to a solid support comprising an affinity capture domain (e.g., streptavidin) corresponding to the affinity domain.

[0012] In some embodiments, the method can include: using a 3'-5' single-stranded nuclease or multiple 3'-5' nucleases to remove any overhanging polynucleotide sequence at the 3' end of the oligonucleotide hybridized complementary chain to form a blunt-ended duplex of the 3' end of the complementary sequence (complement) and the 5' end of the oligonucleotide; attaching (e.g., connecting, linking or otherwise fusing) the blunt-ended duplex to a second adaptor comprising a second sample tag to form a second fusion product, the second fusion product comprising, in the 5' to 3' direction: the upper strand of the first adaptor, the oligonucleotide fragment and the second adaptor; and / or amplifying the second fusion product to sequence one or both of the strands.

[0013] In some embodiments, it may be desirable to combine polynucleotide compositions for multiplex analysis. For example, polynucleotide compositions (e.g., comprising genomic polynucleotides, cellular polynucleotides, organelle polynucleotides, cell-free polynucleotides or other polynucleotides from the same or different samples, specimens, cells, fluids, tissues, organisms or other materials) can be combined before fragmentation or at any step of the methods disclosed herein, for example, after adapter fusion or after linear amplification. Therefore, in some embodiments, methods may include combining adapter fusion products derived from a plurality of separated polynucleotide compositions (e.g., comprising genomic polynucleotides, cellular polynucleotides, organelle polynucleotides, cell-free polynucleotides or other polynucleotides from the same or different samples, specimens, cells, fluids, tissues, organisms or other materials). For example, a method can include combining a linear amplification product (e.g., from a first adaptor fusion, nick translation, and linear amplification) with a further linear amplification product (e.g., from a second adaptor fusion, nick translation, and linear amplification), the further linear amplification products each comprising, in the 5' to 3' direction: a sequence complementary to a linear amplification annealing site; a sequence of a further sample tag; optionally, a sequence of a UMI; a sequence of a portion of a further adaptor upper strand; and sequences of polynucleotide fragments of a further population of fragments.

[0014] In some embodiments, the method may include repeating the adapter fusion step with a second DNA adapter and a double-stranded polynucleotide fragment of the second fragment population to form a further fusion product, wherein the first adapter upper strand comprises a sample tag, and wherein the second adapter comprises a lower strand and an upper strand (e.g., a longer upper strand). The second adapter upper strand may comprise, from 5' to 3': a sequence of at least 8 nucleotides complementary to a linear amplification annealing site; a sample tag different from the first adapter sample tag; optionally, a unique molecular identifier (UMI); and a sequence complementary to the second adapter lower strand. The second adapter lower strand may comprise a non-extendable 3' end, and optionally may be free of a 5' phosphate, free of a sample tag, free of a UMI, and free of a linear amplification annealing site. In some embodiments, the polynucleotide fragments of the second population may comprise a target sequence. A further fusion product may comprise a 3' end of the second adapter upper strand fused to the 5' end of the polynucleotide fragments of the second population and a nick comprising the unfused 5' end of the second adapter lower strand and the 3' end of the polynucleotide fragments of the second population. The method may include combining the fusion product with a further fusion product to form a combined fusion product.

[0015] In some embodiments, the step of contacting the fusion products with a nick translation polymerase can further include contacting the combined fusion products with a nick translation polymerase for templated addition of nucleotides to the 3' ends of the polynucleotide fragments to form a combined nick translation product comprising a 3' extension of the polynucleotide fragments, the extension being complementary to the corresponding adapter upper strand. The step of contacting the nick translation products with a primer having a sequence complementary to the linear amplification annealing site can further include, in some embodiments, contacting the combined nick translation products with a primer and a polymerase to produce a linear amplified combined nick translation product, wherein the linear amplified combined nick translation product can include, in the 5' to 3' direction: a sequence complementary to the linear amplification annealing site; a sequence of one of the corresponding sample tags; optionally, a sequence of a UMI; a sequence of a portion of the corresponding adapter upper strand; a sequence of one of the polynucleotide fragments; and optionally, a sequence complementary to a portion of the corresponding adapter lower strand.

[0016] According to some embodiments, a method for enriching a target sequence can include contacting a fragmented polynucleotide population with a ligase and a first adaptor, the first adaptor comprising a bottom strand and a top strand (e.g., the longer top strand), wherein (i) the bottom strand comprises, in the 5' to 3' direction: 5'-OH; at least 10 nucleotides complementary to the top strand; and optionally, an inverted dT; and (ii) the top strand comprises, in the 5' to 3' direction: a sequence complementary to a linear amplification annealing site; optionally, a sample tag; a unique molecular identifier (UMI); and a sequence complementary to the bottom strand, wherein the top strand and the bottom strand optionally and independently comprise one or more deoxyuridines (e.g., distributed along the length of the respective strands) and wherein the contacting produces a double-stranded fusion product comprising the 3' end of the top strand of the adaptor fused to the 5' end of the polynucleotide fragment and a nick comprising the unfused 5' end of the bottom strand of the adaptor and the 3' end of the polynucleotide fragment. In some embodiments, the method can further include contacting the double-stranded fusion product with a nick translation polymerase and nucleotide triphosphates to form a nick translated duplex polynucleotide, wherein the duplex comprises: an upper strand comprising, in the 5' to 3' direction: an adaptor upper strand, a positive strand of one of the polynucleotide fragments, and a sequence complementary to the adaptor upper strand; and a lower strand comprising, in the 5' to 3' direction: an adaptor upper strand, a negative strand of one of the polynucleotide fragments, and a sequence complementary to the adaptor upper strand; and optionally contacting the nick translated duplex polynucleotide with a single nucleotide excision reagent (e.g., which removes deoxyuridine) to form a polynucleotide duplex comprising a positive strand and a negative strand, each of which comprises a single nucleotide gap in the adaptor upper strand of the nick translated duplex polynucleotide, the gap defining oligonucleotides of different lengths. In some embodiments, the method can further include contacting the nick translated duplex polynucleotide with a linear amplification primer having a sequence complementary to a linear amplification annealing site to form an annealed duplex. According to some embodiments, the method may further include contacting the annealed duplex with a polymerase to form a primer extension product, the primer extension product comprising, in the 5' to 3' direction: a sequence corresponding to at least a portion of the upper strand of the adapter; and a sequence corresponding to at least a portion of the positive strand of one of the polynucleotide fragments. Amplification (e.g., linear amplification) can be achieved by repeating the annealing and polymerization steps at least once (e.g., 5-10 cycles, 5-20 cycles, 5-30 cycles, 10-50 cycles, or >50 cycles). In some embodiments, the method may further include contacting the primer extension product with a target separation probe comprising an affinity domain and a target-specific oligonucleotide to form a target probe mixture, the target probe mixture comprising: a primer extension product; a target separation probe; and, if one or more target sequences are present in the fragmented polynucleotide population, a target complex comprising a primer extension product, the primer extension product having a target sequence hybridized with the target-specific oligonucleotide of the target separation probe.According to some embodiments, the method may further include contacting the target probe mixture with a solid support comprising an affinity capture domain to form an affinity complex comprising an affinity domain bound to the affinity capture domain, the affinity capture domain corresponding to the affinity domain of the target separation probe. In some embodiments, the method for enriching the target sequence may include separating the affinity complex from unbound primer extension products and unbound target separation probes to form an enriched target sequence composition.

[0017] In some embodiments, the method may include: A-tailing the fragmented polynucleotides prior to fusion with the first adapter, for example, wherein the upper strand of the adapter further comprises a 3'T or dU. The method may include (for example, for multiplex analysis) repeating all method steps, wherein the population of fragmented polynucleotides of each repeated first adapter fusion step is different from all previous first adapter fusion steps, and wherein the sample labels of each first adapter fusion step are different from all previous first adapter fusion steps; and optionally merging the affinity complexes from each repetition (or cycle). The method may include one or more optional washing steps, for example, to remove (at least a certain portion of) fragments lacking the target sequence after the target complex is formed and / or after the affinity complex is formed. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1A-1B Shown is a schematic diagram of an example method for forming an enriched library of target sequences from a complex (eg, genomic) DNA sample. Figure 1A A simple flow chart showing an example enrichment workflow. Figure 1B An example workflow is shown.

[0019] Figure 2A-2B Shown is a schematic diagram of an example method for forming an enriched library of target sequences from a complex (eg, genomic) DNA sample. Figure 2A A simple flow chart showing an example enrichment workflow. Figure 2B An example workflow is shown.

[0020] Figure 3A-3C The sequencing results of three low input samples are shown, each enriched for a different target, a total of 75 kb ( Figure 3A ), a total of 227kb ( Figure 3B ), a total of 1100kb ( Figure 3C ). DETAILED DESCRIPTION

[0021] In some embodiments, the present disclosure relates to methods and compositions for preparing polynucleotide libraries enriched for target sequences from source materials (e.g., samples containing or constituting biological fluids, tissues, and / or specimens). Methods and compositions can provide effective enrichment of targeted polynucleotides. Enrichment can include increasing the relative abundance of targets from source materials (which can exist in low abundance) and generated libraries (which can exist in higher abundance). In some embodiments, methods include attaching (e.g., connecting, linking, or otherwise fusing) adapters to fragments of interest, nick translation, amplification (e.g., linear amplification), and target sequence selection using, for example, affinity tags.

[0022] Targeted genomic analysis applications may include, for example, analysis of as few as one target, which is a target of one or several bases, to identify clinically actionable mutations. Such applications may include, optionally, analysis of up to 1 million (or more) targets consisting of 50-100 trillion bases to sequence the entire exome or entire genome of a pathogen enriched from a host sample to find variants of interest. PCR methods generally capture a single to a few targets, while traditional hybrid capture of whole genome libraries amplified by PCR effectively captures very large numbers of targets. Medium-sized panels, used for highly sensitive interrogation of hundreds or thousands of targets, are not well treated by these methods. The multiplexing capacity of PCR is limited, and multiple separate reactions are required to cover a target set of this size. Due to the non-specific capture of some off-target fragments, the specificity of traditional hybrid capture target library fragments decreases when the group size is small. Additionally, bias may be introduced during PCR amplification prior to enrichment, and polymerase errors introduced during PCR are amplified.

[0023] In some embodiments, the present disclosure provides methods for obtaining the advantages of existing hybridization techniques while increasing specificity by performing hybridization capture of target fragments and / or inhibiting conversion of off-target fragments into full-length library molecules before the target fragments are fully converted into libraries having the necessary 3' and 5' fixed sequences. In addition, the present disclosure also provides methods that include amplification, which is necessary for low input samples in order to increase sensitivity, but utilizes linear amplification rather than PCR, thereby avoiding the introduction of significant amplification bias and / or avoiding errors introduced by amplification polymerases.

[0024] General considerations

[0025] The various aspects of the present disclosure can be further understood according to the embodiments, section titles, drawings, descriptions and examples, none of which should be interpreted as limiting the entire scope of the present disclosure in any way. Therefore, the claims listed below should be interpreted according to the full breadth and spirit of the present disclosure.

[0026] Each of the individual embodiments described and shown herein has discrete components and features that can be easily separated or combined with the features of any other several embodiments without departing from the scope or spirit of the present teachings. Any narrated method can be performed in the order of the events described or in any other order that is logically possible. Unless otherwise indicated, all reagents mentioned in this disclosure can be obtained from New England Biolabs, Inc. (Ipswich, MA).

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Nevertheless, for clarity and ease of reference, certain terms are defined herein with respect to various embodiments of the present disclosure.

[0028] Numerical ranges include the numbers defining the range. All numbers are understood to encompass the midpoints of integers above and below the integers, i.e., the number 2 encompasses 1.5-2.5. The number 2.5 encompasses 2.45-2.55, etc. When sample values ​​are provided, unless otherwise specified, for example, each individually may represent a median value within the numerical range, and together may represent an extreme value within the range.

[0029] Sources for common terms and symbols can include: standard papers and texts such as Kornberg and Baker, DNA Replication, second edition (WH Freeman, New York, 1992); Lehninger, Biochemistry, second edition (Worth Publishers, New York, 1975); Strachan and Read, Human Molecular Genetics, second edition (Wiley-Liss, New York, 1999); Eckstein, ed., Oligonucleotides and Analogs: A Practical Approach (Oxford University Press, New York, 1991); Gait, ed., Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, 1984); Singleton et al., Dictionary of Microbiology and Molecular biology, second edition, John Wiley and Sons, New York (1994) and Hale & Markham, the Harper Collins Dictionary of Biology, Harper Perennial, NY (1991), etc.

[0030] As used herein and in the appended claims, the singular forms "a", "an", and "an / kind" include plural reference unless the context clearly dictates otherwise. For example, the term "protein" refers to one or more proteins, i.e., a single protein and a plurality of proteins. It should also be noted that the claims may be drafted to exclude any optional elements. Therefore, this statement is intended to serve as antecedent basis for such exclusive terminology as "only", "only", etc., in connection with the recitation of claim elements or the use of a "negative" limitation.

[0031] In the context of the present disclosure, "adapter" refers to a polynucleotide that is configured to attach (e.g., connect, link or otherwise fuse) to a desired polynucleotide (e.g., a fragmented polynucleotide). An adaptor can be linear and have two ends. One end can be suitable for connecting to other polynucleotides. For example, the end can be flat (e.g., for blunt end connection), have a single nucleotide overhang connection (e.g., for connection to a T or U overhang of an A-tailed polynucleotide), or have a longer overhang (e.g., for connection to 2-20 nucleotides of a polynucleotide with a complementary overhang). An adaptor can include a non-extendable 3' end. For example, each 3' end of an adaptor can have a reverse dT (e.g., TriLink Biotechnologies), which is connected to the penultimate nucleotide by a 3'-3' bond connection (linkage) that resists the extension caused by DNA polymerase. The other end of the polynucleotide (e.g., at the far side of the end selected for or suitable for connection) can be the same or different. When different, it can include nucleotides of any length, of any sequence, complementary or non-complementary to the rest of the adaptor. For example, the end can include a long overhang that is not complementary to the strand that would otherwise pair with the adaptor. The adaptor can include a single strand that can hybridize with at least a first portion of the adaptor strand to a second portion of the adaptor strand to form a loop (e.g., including a hairpin).

[0032] A double-stranded adapter may comprise an upper strand and a lower strand, wherein each strand comprises a separate oligonucleotide strand. A double-stranded adapter (e.g., a loop adapter) may comprise an upper strand and a lower strand, wherein a single polynucleotide strand folds upon itself to provide the upper strand and the lower strand (see, e.g., US 8,288,097 and US2012 / 0244525A1).

[0033] In the context of the present disclosure, an "affinity domain" refers to a domain that is capable of binding to a protein with high affinity (e.g., at least 10 -8 M) and a domain that specifically binds to a corresponding affinity capture domain. Exemplary substances with such properties include biotin, DBT, desthiobiotin, digoxigenin, glutathione, heparin, maltose, coenzyme A, protein A, brilliant blue FCF, azorubine, phytoestrogen, nickel, cobalt, zinc, polyhistidine, HA-tag, c-myc tag, FLAG-tag, S-tag, hapten of an antibody, monosaccharide or oligosaccharide ligand of a lectin, hormones, cytokines, toxins, dyes, and vitamins.

[0034] In the context of the present disclosure, an "affinity capture domain" refers to a domain that is capable of binding to a corresponding affinity domain. Exemplary substances with such properties include avidin, streptavidin, neutravidin, maltose binding protein, GST, antibodies, lectins, nickel, cobalt, zinc, and polyhistidine. Further examples include groups that form non-reversible bonds with protein tags, including benzylguanine or benzylchloropyrimidine (SNAP-tag); benzylcytosine (CLIP-tag); halogenated alkyl (HaloTag); CoA analogs (MCP-tag and ACP-tag); trimpethoprim or methotrexate (TMP-tag); FlAsH or ReAsH (tetracysteine ​​tag); substrates for biotin ligase; substrates for phosphopantetheline transferase; and substrates for lipoic acid ligase. Affinity groups are used to selectively enrich samples by affinity purification methods, in which the affinity binding partner is immobilized on a column, bead, microtiter plate, membrane or other solid support.

[0035] In the context of the present disclosure, "attachment", "fusion" and "linking" can be used interchangeably to refer to any means of connecting two (or more) nucleic acid ends, such as by ligases, transposases, topoisomerases, DNA-dependent protein kinases and other end-joining or repair enzymes, wherein the ends can be in the same molecule (e.g., forming a circular nucleic acid molecule from a linear substrate) or in different molecules (e.g., forming a single linear nucleic acid product from two linear substrate molecules). Fusion of two (or more) nucleic acid ends can include forming a covalent bond between the ends (e.g., a phosphodiester bond, a phosphorothioate bond, or any other bond connection). Fusion of double-stranded nucleic acids can include fusing one or both of the 5' end and the 3' end to one or both of the corresponding 3' end and the 5' end of a second double-stranded nucleic acid. Fusion of double-stranded nucleic acids can include fusing the 5' end and the 3' end of the nick to each other. In some embodiments, the fused nucleic acid ends do not include nick translation.

[0036] In the context of the present disclosure, "coverage" refers to the number of times a targeted subset of a polynucleotide population (eg, fragmented genomic DNA) is sequenced.

[0037] In the context of the present disclosure, an "enriched library" refers to a library in which the abundance of one or more targets is increased relative to a reference library. For example, an enriched cell-free fetal DNA library can have a higher abundance of one or more non-invasive prenatal testing targets than a maternal whole blood DNA library or a cell-free DNA library. The number of enriched targets in an enriched library can be 1, more than 1, more than 10, more than 100, more than 1,000, more than 10,000, more than 100,000, or more than 500,000. An enriched library can include enriched targets corresponding to the entire exome of an organism.

[0038] In the context of the present disclosure, "linear amplification" refers to an amplification reaction in which the amount of product increases linearly rather than exponentially with time.

[0039] In the context of the present disclosure, a "linear amplification annealing site" refers to a portion of a polynucleotide having a sequence that is (a) complementary to an amplification primer and (b) unique within the polynucleotide. A linear amplification annealing site can have sufficient complexity to be unique within a given polynucleotide in which it is present. For example, the length of a linear amplification annealing site can be ≥15 nt, ≥20 nt, ≥25 nt, ≥30 nt, ≥35 nt, ≥40 nt, ≥45 nt, or ≥50 nt.

[0040] The term "high sensitivity" in sequencing readout refers to the detection of rare variants that may exist in the genome. For example, in a cancer biopsy, only a small percentage (e.g., 0.1%) of the polynucleotide population from a human sample may contain a sequence variant of interest (e.g., a SNP). Therefore, a method with high sensitivity is needed to detect these rare events. This article describes and is used in Figure 1A-1B The method involving linear amplification illustrated in is a highly sensitive method.

[0041] In the context of the present disclosure, "non-naturally occurring" refers to polynucleotides, polypeptides, carbohydrates, lipids or compositions that do not exist in nature. Such polynucleotides, polypeptides, carbohydrates, lipids or compositions may differ from naturally occurring polynucleotides, polypeptides, carbohydrates, lipids or compositions in one or more aspects. For example, a polymer (e.g., a polynucleotide, polypeptide or carbohydrate) may differ in the type and arrangement of component building blocks (e.g., nucleotide sequence, amino acid sequence or sugar molecule). A polymer may differ from a naturally occurring polymer in terms of the molecule (or molecules) to which it is attached. For example, a "non-naturally occurring" protein may differ from a naturally occurring protein in terms of its secondary, tertiary or quaternary structure by having a chemical bond (e.g., covalent bond, including peptide bond, phosphate bond, disulfide bond, ester bond and ether bond and other bonds) with a polypeptide (e.g., fusion protein), lipid, carbohydrate or any other molecule. Similarly, a "non-naturally occurring" polynucleotide or nucleic acid may include one or more other modifications (e.g., added tags or other moieties) to the 5'-end, 3'-end and / or between the 5'-end and 3'-end (e.g., methylation) of the nucleic acid. A "non-naturally occurring" composition may differ from a naturally occurring composition in one or more of the following respects: (a) having components that are not combined in nature, (b) having components at concentrations not found in nature, (c) omitting one or more components otherwise found in a naturally occurring composition, (d) having a form not found in nature, e.g., dried, lyophilized, crystalline, aqueous, and (e) having one or more additional components beyond those found in nature (e.g., buffers, detergents, dyes, solvents, or preservatives). All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0042] In the context of the present disclosure, "nick translation" of a double-stranded DNA molecule having at least one nick containing a 3'-OH refers to the templated addition of a dNTP starting at the 3'-OH of the nick(s). Nick translation can also include 5' to 3' excision of nucleotides starting from the nick(s). Nick translation can be catalyzed by DNA polymerases, including, for example, E. coli DNA pol I, pol Ik, Taq DNA polymerase, DNA polymerase (New England Biolabs, Inc.), Bst DNA polymerase (eg, large fragment), Bsu DNA polymerase, phi29 DNA polymerase, Therminator TM DNA polymerase, Klenow, DNA polymerase and Deep DNA polymerase. DNA polymerases with nick translation and / or strand displacement activity may be referred to herein as "nick translation polymerases." A "nick" may include a break in the phosphate backbone, with or without a short (e.g., up to 15 nucleotides) gap.

[0043] In the context of the present disclosure, a "polynucleotide population" or "library" refers to a composition comprising a plurality of polynucleotides having different properties (e.g., sequence, length). Each polynucleotide molecule in a polynucleotide population can be unique relative to other polynucleotides in the population. A complex library can have more than 10 4 , 10 5 , 10 6 or 10 7 different nucleic acid molecules, or there may be fewer but longer molecules, where the fewer molecules collectively have more than 10 4 , 10 5 , 10 6 or 10 7 Nucleotides. The example of complex polynucleotide population includes mammalian and human DNA and cDNA library. The polynucleotide population may include or may be derived from part or all of the genomic DNA, organelle DNA, cDNA, mRNA, microRNA, long non-coding RNA or other DNA or RNA of an organism. The polynucleotide population may include or may be derived from artificial DNA or artificial RNA. For example, a polynucleotide population may be prepared by chemically, enzymatically or physically fragmenting part or all of the DNA or RNA of an organism to produce a certain size or size fragment within the desired range. Relative to the corresponding non-enriched library, the complexity of the enriched library may be less than 10%, less than 5%, less than 1%, less than 0.5% or less than 0.1%, less than 0.01%, less than 0.001%, less than 0.0001%, less than 0.00001%, less than 0.000001% or less than 0.00000001%.

[0044] In the context of the present disclosure, "polynucleotide" refers to any one of DNA, RNA and mixtures thereof. Polynucleotides may be single-stranded, double-stranded or partially single-stranded and partially double-stranded. Polynucleotides may have blunt ends, 5' overhangs and / or 3' overhangs. Polynucleotides may be naturally occurring (e.g., purified or otherwise derived from the genome (nuclear or organelle) or cytoplasm (tRNA, mRNA) of an organism) or synthetic. Polynucleotides may include a whole genome, a gene, a DNA fragment or a fragment library. Polynucleotides may have and / or may be described as having a positive strand and a negative strand or an upper strand and a lower strand. Polynucleotides include a wide range of sizes (e.g., 2 nucleotides to 2 million nucleotides or even longer). Shorter polynucleotides (e.g., 2-250 nucleotides) may be referred to as polynucleotides or oligonucleotides.

[0045] In the context of the present disclosure, "sample" refers to a specific source of a specific population of polynucleotide fragments. Depending on its context, a sample can be a specific polynucleotide extracted from a single cell, tissue, or individual biological entity such as a plant, animal, or microorganism.

[0046] In the context of the present disclosure, a "sample tag" refers to a molecular barcode that identifies the sample origin of a population of polynucleotide fragments. Thus, an adaptor attached (e.g., linked, conjugated, or otherwise fused) to each strand in a duplex will have the same sample tag (e.g., Figure 1B , i5 and i7 (Illumina). Prior to sequencing, the sample tag can be included in the first adapter, the second adapter and / or the amplification primer (e.g., PCR primer).

[0047] In the context of the present disclosure, a "strand" refers to a polynucleotide composed of nucleotides linked together by covalent bonds. A double-stranded or duplex polynucleotide (e.g., DNA) comprises two strands - an upper strand or positive strand and a lower strand or negative strand - each strand comprising a sequence complementary to the other strand. Conventionally, the strand designated as the upper strand or positive strand is illustrated with the 5' end on the left and the 3' end on the right, while the strand designated as the lower strand or negative strand is oriented with the 3' end on the left and the 5' end on the right.

[0048] In the context of the present disclosure, "target sequence" refers to the part of the polynucleotide fragment that constitutes or comprises a sequence of interest. The target sequence can be interesting for any reason in a variety of reasons, for example, because it diagnoses a disease, an infectious agent (for example, yeast, bacteria, virus, bacteriophage), phenotype, genotype, allele, variation or other state or condition, or is otherwise associated with a disease, an infectious agent (for example, yeast, bacteria, virus, bacteriophage), phenotype, genotype, allele, variation or other state or condition. The example of the target sequence can include exons, introns, regulatory sequences, single nucleotide polymorphisms (SNPs), gene fusions, copy number variations and insertions / deletions (indels). The analysis of the target sequence can also be used to determine heterozygosity and homozygosity. The target sequence can be derived from continuous or non-continuous nucleotides in the genome. For example, the target sequence can constitute or comprise an expressed eukaryotic gene sequence (e.g., lacking some or all introns), a gene fusion (e.g., a fusion of two genes that may not be naturally occurring and / or may otherwise be (normally) present in separate regions of the genome) and / or intron / exon boundaries. The target sequence can, for example, constitute or comprise all or part of a gene selected from the group consisting of MTOR, DPYD, NRAS, NTRK1, DDR2, ALK, MSH2, MSH6, NFE2L2, IDH1, UGT1A1, VHL, RAF1, MLH1, CTNNB1, PIK3CA, FGFR3, PDGFRA, KIT, KDR, FBXW7, TERTpro, PIK3R1, APC, CSF1R, PDGFRB, FLT4, CCND3, ROS1, ESR1, PMS2, EGFR, CDK6, MET, SMO, BRAF, EZH2, FGFR1, JAK2, C D274, PDCD1LG2, CDKN2A, GNAQ, PTCH1, ABL1, TSC1, GATA3, RET, PTEN, FGFR2, CCND1, CCND2, KRAS, CDK4, FLT3, FLT1, BRCA2, RB1, AKT1, MAP2K1, IDH2, TSC2, TP53, ERBB2, BRCA1, RNF43, SMAD4, STK11, GNA11, MAP2K2, KEAP1, JAK3, AKT2, GNAS, NF2, ARAF, AR, BRIP1, CHEK2, PALB2, RAD51C and RAD51D. In some embodiments, the target sequence can include all or part of an exon.

[0049] In the context of the present disclosure, a "target isolation probe" or "bait" refers to a molecule or complex comprising an affinity domain and a target-specific oligonucleotide.

[0050] In the context of the present disclosure, a "target-specific oligonucleotide" refers to an oligonucleotide having a sequence that is at least partially complementary to a sequence of interest ("target sequence"). The specificity of a target-specific oligonucleotide is conferred by its nucleotide selection. Specificity can also be affected by the stringency of the conditions of contact with another polynucleotide, for example, the contact temperature and the presence or concentration of salt(s), competitor(s), detergent(s), clustering agent(s), etc.

[0051] In the context of the present disclosure, a "unique molecule identifier" (UMI) refers to a unique sequence of at least 6 nucleotides (6N) that, together with other nucleotides similar to the UMI, has sufficient complexity to uniquely label each polynucleotide molecule in a population of polynucleotide molecules. For example, the UMI of each molecule of adaptor 1033 can have a unique sequence. UMI sequences can be random, disordered, or otherwise varied to achieve a desired level of complexity. Longer random unique sequences can be used, for example, 2-15 nucleotides, 6-12 nucleotides, or 8-12 nucleotides.

[0052] The present disclosure provides methods for generating enriched target sequence libraries. Methods according to some embodiments can efficiently generate libraries representing most (eg, all or substantially all) nucleotides in the original sample from low input samples.

[0053] Sample preparation

[0054] In some embodiments, a polynucleotide population can be generated from any source or sample, such as a sample of any organism, including but not limited to plants (e.g., ornamental plants, vegetables, fruits, trees, woody shrubs, grasses, spore-bearing, seed-bearing and other plants), animals (e.g., vertebrates, invertebrates, reptiles, mammals, insects, worms, fish, birds and other animals), bacteria, fungi (e.g., yeast), bacteriophages, viruses, cadaveric tissue, archaeological / ancient samples, any part thereof (e.g., organs, tissues, cells, fluids, solids, biopsies) and any combination thereof. In some embodiments, a sample for fragmentation can include genomic DNA from a mammal (e.g., a human or non-human animal). The mammalian body fluid of interest can include blood, serum, plasma, saliva, mucus, sputum, cerebrospinal fluid, pleural fluid, tears, lactal duct fluid, lymph, sputum, synovial fluid, urine, amniotic fluid and semen. In some embodiments, a sample can be obtained from a subject, such as a clinical specimen of a human subject. According to some embodiments, the sample may include cell-free polynucleotides, including, for example, circulating DNA in body fluids (e.g., peripheral blood from the blood of a subject (e.g., a cancer patient or a pregnant woman)) and DNA in the vascular fluids (e.g., phloem) of plants. In some embodiments, the sample for fragmentation may include genomic DNA from a plant (e.g., leaves, stems, roots, seeds, pistils, stamens, embryos).

[0055] According to some embodiments, methods may include extracting polynucleotides (e.g., genomic DNA) from a biological source material and then fragmenting it mechanically (e.g., by sonication, nebulization, or shearing), enzymatically (e.g., using double-stranded DNA "dsDNA" fragmentation), or Enzymes (New England Biolabs, Ipswich MA), transposases, nucleases) or chemically (e.g., exposure to heat in the presence of divalent metal ions, formalin fixation and paraffin embedding). In some embodiments, a sample can include polynucleotides of a desired size or size range without further fragmentation, for example, where the polynucleotide population is synthetically generated (e.g., in vitro) or collected from circulating cell-free DNA (cfDNA, e.g., ctDNA).

[0056] The polynucleotide fragment population, according to some embodiments, may have a median size of less than 1 kb. For example, the median or average size may be 50 bp to 500 bp or 80 bp to 400 bp, 150 bp–200 bp or 200 bp-300 bp or 300 bp-400 bp or 400 bp-500 bp or 500 bp-600 bp or 600 bp-700 bp). In some embodiments, the polynucleotide fragment population may have a median size of more than 1 kb. For example, the median fragment size may be 1 kb to 5 kb or 2 kb to 10 kb.

[0057] According to some embodiments, when the amount of polynucleotide is limited, the method of the present disclosure can be used. For example, the method can be applied to a polynucleotide population comprising or containing less than 200ng fragmented DNA (e.g., 10pg to 200ng fragmented DNA, 100pg to 200ng fragmented DNA, 1ng to 200ng fragmented DNA, 5ng to 50ng fragmented DNA) or less than 10,000 haploid genome equivalents (e.g., <5,000, <1,000, <500, <100, <10). According to some embodiments, when the amount of polynucleotide is not so limited, the method of the present disclosure can also be used.

[0058] (First) Adaptor attachment

[0059] In some embodiments, a method can include attaching (e.g., ligating, linking, or otherwise fusing) an adaptor (e.g., a double-stranded adaptor) to a polynucleotide fragment to produce a fusion product (labeled fragment). An adaptor can include two separate strands that are hybridized together (e.g., Figure 1B or Figure 2BThe adaptor may be a single strand having portions that hybridize to each other and an inserted single strand region (e.g., a hairpin or loop adaptor). One or both strands of the adaptor may contain one or more (e.g., one, two, or three) modified nucleotides, such as deoxyuridine, 8-oxoguanine, or deoxyinosine. The presence of modified nucleotides may impart desired properties to the adaptor, including, for example, limiting or preventing unwanted exonuclease digestion (e.g., phosphorothioates), reducing or eliminating unwanted secondary structures associated with G-rich regions (e.g., 8-aza-7-deazaG (8-aza-7-deazaG) ("Super G"), or increasing the melting temperature of the duplex (e.g., using locked nucleic acids or by replacing T with 5-hydroxybutynl-2'-deoxyuridine ("Super T") at specific AT pairs). In some cases, the presence of modified nucleotides may provide the user with an effective option for removing the adaptor in a subsequent step, for example, by enzymatic removal (e.g., using a glycosylase) prior to linear amplification.

[0060] According to some embodiments, the method may include generating a population of A-tailed fragments from a population of polynucleotides (e.g., an unamplified, undenatured population of polynucleotides). A-tailing may include, for example, contacting the polynucleotides with a polymerase and dATP under conditions that allow or facilitate the non-templated addition of a single dA to the 3' end (one or more). When the fragments are A-tailed, the adapters may have 3' overhangs of corresponding T or U to facilitate connection. A-tailing the polynucleotide fragments may facilitate connection of the adapters (e.g., by Watson-Crick base pairing of 3'A with 5'T or U), which may be performed using a kit provided by New England Biolabs, Ipswich, MA (e.g., Ultra TM II end repair / add dA tail module ( Ultra TM Alternatively, other means of attaching adaptors to double-stranded DNA in a specific orientation can be employed, or similarly A-tailing can be accomplished by using kits from other suppliers.

[0061] In some embodiments, an adapter comprising an upper chain and a lower chain can be attached (e.g., connected, linked or otherwise fused) to a polynucleotide fragmentation product, wherein the upper chain of the adapter is attached (e.g., connected, linked or otherwise fused) to the positive or negative chain of the fragmented polynucleotide (e.g., connected to the 3' end of the A-tailed fragmented polynucleotide). The upper chain can include, in the 5' to 3' direction: a sequence complementary to the linear amplification annealing site (e.g., an NGS platform-specific sequencing primer); optionally a sample tag; a unique molecular identifier (UMI); a sequence complementary to the lower chain; and optionally nucleotides complementary to A. In some embodiments, the upper chain of the adapter is longer than its lower chain. The lower chain of the adapter can have at least 10 nucleotides (e.g., at least 15 nucleotides). A shorter lower chain may be suitable in some cases. The 5' end of the lower chain of the adapter can include a 5'-OH, for example, in order to block the lower chain from connecting to the lower chain of the polynucleotide fragment. Adaptor ligation can be performed by T4 DNA ligase, circligase, PBCV-1 DNA ligase or other ligases. The ligation product can be optionally separated from the other components of the ligation mixture.

[0062] In some embodiments, after ligation, a region of a hairpin or loop adapter can be cleaved to produce a duplex in which the top and bottom strands are on different molecules. In some cases, the cleavage region of a hairpin adapter can contain a modified residue, such as deoxyuridine, and the base can be cleaved using a glycosylase (e.g., UDG), although other methods are known.

[0063] Strand displacement / nick translation

[0064] The fusion product (labeled fragment) containing a nick (e.g., a nick defined by the unconnected end of the lower chain of the adapter and the A tail of the fragmented polynucleotide) can be contacted with a chain displacement polymerase or a nick translation polymerase for templated addition of nucleotides. The product of either method can be referred to as a nick translation product. Nucleotides can be added, for example, starting from the A tail of the fragmented polynucleotide, and the template is the upper chain of the adapter. The nascent chain of the duplex polynucleotide formed can be complementary to the upper chain of the adapter, and optionally can be free of modified nucleotides (e.g., by performing chain displacement / nick translation in the absence of modified nucleotides). Each chain of the duplex polynucleotide formed can include, in the 5' to 3' direction: the upper chain of the adapter; the polynucleotide fragment; and the nascent chain (which is complementary to the upper chain of the adapter). When the upper chain of the adapter contains one or more modified nucleotides, the product of chain displacement / nick translation can be contacted with a single nucleotide excision reagent (e.g., glycosylase and endonuclease) to remove the modified nucleotides. For example, a single nucleotide excision reagent can remove the base of a modified nucleotide and cleave the phosphodiester backbone at the 3' and 5' sides of the modified base (or the abasic site created by the removal of the modified base). For example, the upper strand of an adaptor comprising deoxyuridine can be contacted with UDG (e.g., Antarctic Thermolabile UDG (New England Biolabs, Ipswich, MA)), for example, at 37°C for 10 minutes. UDG catalyzes the release of free uracil from an adaptor sequence fused to the 5' end of a DNA fragment and creates an abasic site in the adaptor sequence. In a subsequent thermal cycling reaction, the abasic site is susceptible to hydrolytic cleavage and fragmentation at an elevated reaction temperature. Alternatively, UDG can be combined with EndoVIII (e.g., New England Biolabs, Inc.) in combination. Other modified nucleotide / reagent combinations may also be used. The site of a removed single nucleotide (e.g., deoxyuridine or other modified nucleotide) can define oligonucleotide ends of different lengths, depending on, for example, the position of the removed nucleotide in the initial chain, but in any case will be shorter than the initial chain. When excised, continuous modified nucleotides may be referred to as single nucleotide gaps, continuous single nucleotide gaps, or nucleotide gaps. Excision of two modified nucleotides flanking unmodified nucleotides can release the single nucleotide. At a working reaction temperature (e.g., 10°C to 40°C (or higher)), the single nucleotides and oligonucleotides formed by the action of the single nucleotide excision reagent may not maintain base pairing with another chain. Therefore, they may be lost in subsequent steps. In some embodiments, by optionally including a specific cleaning step, the nucleotides and oligonucleotides formed by the action of the single nucleotide excision reagent can be removed / separated from the remaining chain containing the polynucleotide fragment and the nascent chain from the nick translation.

[0065] Linear amplification

[0066] According to some embodiments, the nick translation product (e.g., remaining after removal of the modified nucleotide) can be linearly amplified. Linear amplification can be performed by contacting the fusion product (e.g., simultaneously with or after removal of the modified nucleotide) with a polymerase, dNTPs, and a linear amplification primer to produce a reaction mixture. In some embodiments, the polymerase can be a thermostable polymerase, and the reaction mixture can be thermally cycled at least once (e.g., at least 5 times, or at least 10 times, or at least 20 times) to produce multiple copies of each labeled fragment, wherein the number of copies corresponds to the number of cycles. The NEB NextUltra II Master Mix (NEBNext Ultra II Linear amplification is performed using a PCR Master Mix containing Q5 DNA polymerase (New England Biolabs, Ipswich, MA), but other polymerases can also be used. The products of linear amplification can have a copy of the linker strand molecule barcode on the 3' side of the polynucleotide fragment and can be referred to as 5'-labeled amplification products.

[0067] In some embodiments, a polymerase that is active at lower temperatures can be used (e.g., Klenow exo-, Bsu large fragment, and phi29 for moderate temperature reactions (25–40°C), and Bst DNA polymerase large fragment for higher temperature (50–65°C) reactions), and the reaction mixture can be incubated with or without thermal cycling to produce multiple copies of each labeled fragment. For example, linear amplification can be performed using isothermal amplification (e.g., instead of thermal cycling). Examples of isothermal amplification can include ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), self-maintaining sequence amplification (3SR), Qβ replicase-based amplification or rolling circle replication, nucleic acid sequence-based amplification (NASBA), repair chain reaction (RCR), boomerang DNA amplification (BDA), helicase-dependent amplification (HDA).

[0068] According to some embodiments, linear amplification can be performed by denaturing the polynucleotide to be amplified (e.g., at 98°C for 30 seconds), contacting the denatured polynucleotide with a polymerase, dNTPs, and a linear amplification primer to produce a reaction mixture, and thermally cycling the reaction mixture at least once (e.g., at least 5 times, at least 10 times, at least 15 times, or at least 20 times). Thermal cycling can be performed by the following steps: (1) a temperature above 90°C (e.g., 98°C) for at least 5 seconds, (2) a temperature below 60°C (e.g., 55°C) for at least 5 seconds, and (3) a temperature in the range of 65°C to 80°C (e.g., 70°C to 75°C) for at least 10 seconds. At a first temperature, the polynucleotide fragments are denatured. At a next temperature, the linear amplification primer anneals to the 3' end of the adapter sequence. At a third temperature, a polymerase (e.g., Q5 polymerase) extends the linear amplification primer. Other thermal cycling conditions are known and can be readily used.

[0069] In some embodiments, it may be desirable to perform linear amplification using a polymerase with a low error rate (e.g., 4x to 8x fewer errors than Taq polymerase). Linear amplification may be performed using a proofreading DNA polymerase that may have 3' to 5' exonuclease activity. Examples of proofreading thermostable polymerases include Pfu (Agilent Technologies, Santa Clara, CA), Pwo (Roche, Basel, Switzerland), Tgo (Roche, Basel Switzerland), (New England Biolabs, Ipswich, MA), DEEP (New England Biolabs, Ipswich, MA), KOD HiFi (Novagen, Madison, WI), PFX50 TM (Invitrogen, Waltham, MA), HERCULASE II TM (Agilent Technologies, Santa Clara, CA), PLATINUM PFX TM (Life Technologies, Waltham, MA) and ProofStart TM (Qiagen, Hilden, Germany). Other examples of proofreading thermostable polymerases include, but are not limited to (Thermo Fisher Scientific, Waltham, MA), PFUULTRA TM(Agilent Technologies, Santa Clara, CA), PFUULTRA TM II (Agilent Technologies, Santa Clara, CA), IPROOF TM (Bio-Rad, Hercules, CA), Q5 polymerase and KAPAHIFI TM (Kapa Biosystems, Wilmington, MA). These polymerases can produce at least 20x fewer errors on average than Taq polymerase and can be readily used herein. Linear amplification can be performed using a non-proofreading DNA polymerase. Examples of non-proofreading thermostable polymerases (i.e., thermostable polymerases that do not have 3' to 5' exonuclease activity) include, but are not limited to, Taq and Tth.

[0070] In some embodiments, linear amplification reduces or avoids amplification bias and / or sequence mis-amplification (e.g., nucleotide incorporation errors that may occur in early rounds of amplification). Linear amplification can provide a more streamlined process (e.g., relative to nonlinear amplification) by avoiding the need for additional steps or measures to ensure product quality. For example, nonlinear amplification methods can omit The digestion step is performed to retain the adapters at both ends of the fragment, but will subsequently benefit from the inclusion of blocking oligonucleotides to retain the specificity of subsequent bait hybridization. Such oligos will be required to prevent the bait from hybridizing to the target fragment and the adapter sequence of the target fragment from hybridizing to the complementary adapter sequence of a random non-target fragment. Such hybridization can result in the formation of a "daisy chain" amplification product containing target molecules and non-target molecules. However, in some embodiments, nonlinear amplification can be an option, for example, in which case mass loss can be acceptable and / or in which case additional precautions are included to offset mass loss.

[0071] Hybridization

[0072] Linear amplification products (e.g., 5'-labeled amplification products) can be contacted (e.g., hybridized) with target-specific oligonucleotides to produce complexes. In some embodiments, target separation probes can include target-specific oligonucleotides connected (e.g., covalently linked) to affinity domains (e.g., biotin). Target-specific oligonucleotides can be designed to hybridize with any target, including targets of diagnostic and / or therapeutic interest (e.g., target sequences in cancer-related genes) and targets of breeding interest (e.g., traits, genotypes, phenotypes, and markers thereof). Contacting linear amplification products with target separation probes can include contacting linear amplification products with target separation probes having different specificities, at least 1, at least 5, at least 10, at least 100, at least 1,000, or at least 10,000 target-specific oligonucleotides, thereby separating and enriching fragments with different elements of target regions or genomes. Each target-specific oligonucleotide can have a length of 30 to 100 nucleotides. Under certain conditions / situations, shorter and longer target-specific oligonucleotides can be used. For example, in the case where the polynucleotide fragments to be evaluated are small, smaller targets may be desired, such as fragments derived from urine cfDNA. When evaluating small genomes (wherein shorter sequences maintain uniqueness / specificity), smaller targets may also be desired or acceptable. In some embodiments, target-specific oligonucleotide pairs may be used, wherein one member of the pair hybridizes to the upper strand of the target, and the other member of the pair hybridizes to the lower strand of the target.

[0073] The target sequence can be located at the 3' end of the region of interest. In some embodiments, biotinylated target specific oligonucleotides are added to a hybridization solution containing a pool of DNA fragments. The hybridization solution containing the target specific oligonucleotides and DNA fragments is then incubated so that the target specific oligonucleotides are hybridized with the amplified product of the 5' mark comprising the target sequence. This hybridization can be performed under relatively high stringency or relatively low stringency. If low stringency conditions are adopted, a large amount of non-specific binding with the target specific oligonucleotides may occur. The sequence of non-specific binding can be removed by processing with 3'-5' single-stranded exonuclease and double-stranded exonuclease (e.g., exonuclease III) in subsequent steps.

[0074] In some embodiments, the complex (e.g., a target separation probe comprising a target region that hybridizes to a labeled fragment) can be captured on a support by an affinity capture domain (e.g., streptavidin) that is attached (e.g., covalently) to the support. The labeled fragments containing the target can thereby be enriched or separated from the labeled fragments that do not contain the target. In some embodiments, after the 5' labeled amplification product is hybridized with the target specific oligonucleotide, streptavidin-coated magnetic beads can be added to the reaction mixture. The magnetic beads can be separated magnetically and then washed to enrich the complex containing the 5' labeled amplification product. Alternatives to biotin include SNAP- (New England Biolabs, Ipswich, MA), which is a protein that reacts with benzylguanine and can be modified to bind to affinity capture domains.

[0075] The solid support may comprise a matrix formed by or coated with a capture domain.The solid support may be, for example, a bead (including magnetic beads), a column, a porous matrix or a flat surface formed by, for example, plastic or paper.

[0076] Generate 3' blunt ends

[0077] The affinity-captured complex, in some embodiments, may have a 3' overhang relative to the 5' end of the hybridized target-specific oligonucleotide. The 3' overhang may include one or more 3' nucleotides of the fragmented polynucleotide and / or one or more nucleotides corresponding to the upper chain of the adapter. The 3' overhang may be removed by contacting the affinity-captured complex with a single-stranded 3'-5' exonuclease to produce a flat end flush with the 3' end of the target sequence. One or more single-stranded 3'-5' exonucleases may be used alone or in combination to catalyze the gradual removal of single nucleotides from the 3' end of single-stranded DNA to form a flat end. For example, exonuclease I and exonuclease T may be used alone or in combination. The 3'-5' single-stranded exonuclease may trim the 3' end of the captured 5'-labeled amplification product until it is flush with the target sequence. The blunt end can include a 5' overhang (e.g., a 5' overhang of 1-5 nucleotides), for example, where the 3'-5' single-stranded exonuclease trims the 3' end of the captured 5'-tagged amplification product slightly beyond the target sequence. A 3' nuclease reaction buffer containing one or more single-stranded 3' exonucleases can, in some embodiments, be added to the captured complex (which still contains the 5'-tagged amplification product) to produce a reaction mixture. After incubation of the reaction mixture (e.g., at 25°C for about 10 minutes, then at 37°C for 5 minutes), the captured complex can be separated from the remaining mixture (e.g., by magnetism in the case where the affinity capture domain is bound to magnetic beads, or by decanting, pipetting or otherwise removing liquid bound to the surface of the tube or plate by the affinity capture domain) and washing. Since the exonuclease-treated complex is still connected to the carrier (e.g., beads, tube, plate), the mixture can be discarded.

[0078] (Second) Adaptor Fusion

[0079] According to some embodiments, a 3' adapter (e.g., a double-stranded adapter) can be attached (e.g., connected, linked or otherwise fused) to the 3' end of the captured polynucleotide fragment of the exonuclease-treated complex to produce a 3'-tagged polynucleotide fragment chain containing the target sequence, which polynucleotide fragment can also remain labeled at its 5' end since the previous (first) adapter fusion. For example, the captured complex (e.g., after washing) can be contacted with a 3' adapter, a ligase and / or a ligation buffer and incubated for an appropriate time and an appropriate temperature to allow ligation. In some embodiments, the 3' adapter can include a blocking portion at its 3' end (one or more), for example, in which case the resulting ligation product can be expected to be resistant to 3'-5' double-stranded DNA exonucleases. The blocking portion can include one or more thiophosphates at the 3' end, have a single-stranded portion at the 3' end, or have a hairpin structure that becomes single-stranded after being partially digested. In some embodiments, a 3' adaptor can have a long (e.g., ≥3nt, ≥4nt, ≥5nt, ≥10nt, ≥20nt, ≥25nt, ≥50nt, or ≥100nt) 3' single-stranded overhang that makes it resistant to digestion by a double-stranded nuclease.

[0080] As an example, a 3' adapter sequence and T4 DNA ligase can be added to the connection mixture to connect the 3' adapter to the target sequence with a flat end. It can be an alternative to add an A tail to the 3' end of the target sequence to connect to the adapter with a complementary T overhang. Other connection methods known in the art can be used, including, for example, by connecting using, for example, a circular ligase or a Taq ligase, to connect the 3' adapter sequence to the target sequence. In this example, the 3' adapter is double-stranded, and its upper chain is connected to the 3' end of the polynucleotide sequence fragment, and its lower chain contains several deoxyuridine residues or other modified nucleotides, as described above. The positive strand of the 3' adapter can include a 3' adapter sequence (e.g., a NGS platform-specific sequencing primer site and a library amplification primer site). After incubation, for example, incubation at 20°C for 15 minutes, the connection product (e.g., a complex in which the 3' adapter connected is still bound to the affinity capture domain and the carrier) can be separated (e.g., using magnetism) from the connection mixture. The separated ligation mixture (now lacking ligation product) can be discarded, since the ligation product (which comprises a complex including the 5' and 3' labeled strands comprising the target sequence) remains attached to the vector.

[0081] Sample cleanup and amplification

[0082] In some embodiments, the second adapter fusion product can be cleaned up, which includes a strand that contains a target sequence and is labeled at both the 5' end and the 3' end. For example, the strand that contains a target sequence and is labeled at both the 5' end and the 3' end can be separated or isolated from an unattached target separation probe, a target separation probe connected to the lower strand of the 3' adapter, and a target exopolynucleotide (e.g., a polynucleotide lacking a target sequence) by contacting the second adapter ligation product with a double-stranded 3'-5' exonuclease that catalyzes the progressive removal of single nucleotides from the 3' end of the duplex DNA and also cleaves non-basic sites. The double-stranded 3'-5' exonuclease can eliminate any remaining double-stranded target exoDNA molecules.

[0083] As an example, the magnetic beads can be washed and resuspended in a 3'-double-stranded exonuclease buffer. Double-stranded 3'-5' exonucleases (e.g., exonucleases III) can be added to form a mixture, and the exonuclease mixture can be incubated (e.g., at 37°C for 15 minutes) to remove any remaining non-target sequences containing unprotected or accessible double-stranded 3' ends. UDG or another deglycosylase can also be added to remove bases from modified nucleotides (e.g., deoxyuridine) from the 3' adapter negative strand. In this example, the target-specific oligonucleotide is allowed to remain hybridized with the target sequence, and magnetic beads can be separated and washed from the remaining reaction mixture using magnetism. The remaining reaction mixture can be discarded because the exonuclease-treated ligation product (which contains a complex including 5' and 3' labeled chains containing the target sequence) is still connected to the beads. The labeled chain can be made insensitive to 3'-5' exonucleases so that it is not degraded during this exonuclease treatment.

[0084] Optionally, the strand comprising the target sequence and being labeled at both the 5' and 3' ends can be amplified by PCR, for example, by contacting the strand with a first primer that hybridizes to a portion of the 3' adapter and a second primer that hybridizes to a linear amplification primer sequence of the first adapter to produce a PCR product. The contacting can further include contacting the strand with a PCR mixture comprising water and a PCR master mix (e.g., a master mix comprising a polymerase, dNTPs, metal ions, salts and / or buffers). The PCR reaction conditions can include (a) a temperature above 90° C. (e.g., 98° C.) for at least 30 seconds, (b) 18 cycles of: (1) a temperature above 90° C. (e.g., 98° C.) for at least 10 seconds, (2) a temperature in the range of 60° C. to 70° C. (e.g., 62° C.) for at least 15 seconds, and (3) a temperature higher than step (2) (e.g., 72° C.) for at least 20 seconds, and (c) a temperature of 72° C. for at least 3 minutes. According to some embodiments, the strand comprising the target sequence and being labeled at both the 5' and 3' ends is not amplified.

[0085] Sequencing

[0086] According to some embodiments, a strand comprising a target sequence and labeled at both the 5' and 3' ends (e.g., with an appropriate sequencing compatible sequence) - whether or not amplified - can be sequenced (e.g., by any desired sequencing method). For example, the strand can be sequenced by a next generation sequencing method, using appropriate primers to obtain at least 10,000, at least 50,000, at least 100,000, at least 500,000, at least 1M, at least 10M, at least 100M, or at least 1B sequence reads (e.g., using Illumina's reversible terminator method primer extension, Roche's pyrophosphate sequencing (454), Life Technologies' ligation sequencing (SOLiD platform), Life Technologies' Ion Torrent platform, MGI's CoolMPS, Oxford Nanopore sequencing, and Pacific Biosciences' fluorescent base cleavage method, etc.). The readout can be a paired end readout. The sequence requiring the selected sequencing method can be included in any desired adapter and / or primer, including a second adapter, a PCR primer used after the second adapter is connected, or both.

[0087] Examples of sequencing methods are described in the following references: Margulies et al. (Nature 2005 437:376–80); Ronaghi et al. (Analytical Biochemistry 1996 242:84–9); Shendure (Science 2005 309:1728); Imelfort et al. (Brief Bioinform. 2009 10:609-18); Fox et al. (Methods Mol Biol. 2009; 553:79-108); Appleby et al. (Methods Mol Biol. 2009; 513:19-39); English (PLoS One. 2012 7:e47768); and Morozova (Genomics. 2008 92:255-64), which are incorporated by reference for a general description of the methods and the specific steps of the methods, including all starting products, reagents, and final products of each step. Sequence reads can be analyzed computationally to identify sequence variations in a sample, such as point mutations, deletions, insertions, and rearrangements.

[0088] Multiplexing

[0089] Advantages of multiplexing include: (a) being able to analyze a large number of samples in one sequence reaction while maintaining a means of tracking the source of each polynucleotide and each sample from which it comes; (b) merging samples can improve efficiency and reduce workflow costs for enriching targets and sequence samples. Multiplexing as described herein can involve merging two, tens, hundreds, or thousands of samples.

[0090] In some embodiments, the adapter fused to the fragment in the initial step of the method can have a sample tag, and the reaction can be multiplexed by combining samples from different sources (e.g., each source has its own tag) into a pool. A pool can be distinguished by its sample tag (e.g., from other samples or pools). In some embodiments, the method can include attaching (e.g., connecting, linking, or otherwise fusing) a double-stranded adapter to a separate polynucleotide fragment from a single sample with a first sample tag, and then combining the fused polynucleotide fragment with a polynucleotide from one or more other samples with one or more other sample tags. If the sample is subjected to linear amplification, an adapter containing an upper strand can be attached (e.g., connected, linked, or otherwise fused) to the 5' end of the sample DNA, the upper strand comprising, in the 5' to 3' direction: a sequence complementary to the linear amplification annealing site; optionally a sample tag; a UMI; a sequence complementary to the lower strand; and optionally nucleotides complementary to A. During linear amplification, primer extension produces a 5' labeled amplification product. Since this reaction can be cycled multiple times and multiple copies of labeled polynucleotide fragments are generated, this strategy can be used for high depth coverage sequencing needs, such as analyzing cfDNA. Alternatively, if the sample is not linearly amplified, an adapter sequence with a sample tag and optionally a UMI can be attached (e.g., connected, linked, or otherwise fused) to the 5' end of the sample DNA. This strategy is suitable for low depth coverage sequencing needs for samples that are not limited, such as genotyping.

[0091] In certain multiplexing embodiments, sample preparation, fragmentation, repair, and A-tailing steps may be performed in parallel using multiple samples as described herein. The double-stranded adapter may comprise a lower strand and a longer upper strand, the longer upper strand comprising a sample tag located on a single-stranded extension between the first single-stranded adapter sequence and the duplex region comprising a sequence complementary to the lower strand. Each sample may be prepared to comprise a different sample tag, wherein each labeled polynucleotide fragment may be traced back to the sample from which it originated by its sample tag.

[0092] As shown, after all samples are attached to adapters having sample tags and optionally UMI sequences, the samples can be combined in a single container and the remaining enrichment steps can be performed together. Optionally, the samples can be combined after linear amplification. After merging, the method can include hybridizing the adapter-labeled sample pool with a target-specific oligonucleotide to produce a complex. The complex can be bound to a solid support, thereby enriching for 5'-labeled molecules containing the target sequence. If the target-specific oligonucleotide is biotinylated, enrichment can be performed using a support containing streptavidin (e.g., magnetic streptavidin beads). Next, in some embodiments, the method can include treating the complex with a 3'-5' single-stranded nuclease to remove any overhanging 3' ends from the product molecules and produce a blunt end at the 3' end of the target sequence. However, this step is optional and a second adapter can be added by other means. The second double-stranded adapter can be attached (e.g., connected, linked or otherwise fused) to the blunt end of the exonuclease-treated complex, thereby adding the 3' adapter sequence to the 3' end of the target sequence to produce a 5' and 3' labeled chain containing the target sequence. Other fusion strategies can be used in this step. For example, the exonuclease-treated complex can be A-tailed, and a T-tailed adapter can also be used. One chain (e.g., the upper chain) of the second double-stranded adapter can be resistant to 3'-5' double-stranded DNA exonuclease due to the 3' blocking portion. In these embodiments, the method can include treating the connection product with a 3'-5' double-stranded exonuclease. Then, using a first primer that hybridizes to the 3' adapter sequence and a second primer that hybridizes to the complementary sequence of the first adapter sequence, the 5' and 3' labeled chains are amplified by PCR to produce an amplified product. In this step, a sample tag can be added to identify the sample pool in the multiplex reaction.

[0093] The amplification product can be sequenced by any convenient method to produce a sequence read comprising a sequence, at least a portion of the target sequence and a sample tag or its complementary sequence. During the analysis, the sequence read can be assigned to the sample according to the sample tag in the sequence read. This method can be implemented in a high throughput format. As few as 1, as many as 96 samples or as many as 384 or more samples (each sample having a different sample tag) can be merged together, wherein the pool is labeled with a single sample tag on the 3' adapter. Then, these merged samples each containing a single sample tag can be merged into a larger pool containing multiple sample tag sequences to be analyzed in a single sequencing reaction. A single sequencing reaction can include multiple enriched preparations of 3' adapter and 5' adapter fused polynucleotide target sequences from one or more samples, 2 or more samples, 3 or more samples, 5 or more samples, 10 or more samples, 50 or more samples, 100 or more samples, 500 or more samples, 1000 or more samples, 5000 or more samples, up to and including about 10,000 or more samples, wherein the samples can be obtained from the same or different sources. For example, the sample can be a plant extract, and the source can be a different plant. In this example, the original individual polynucleotide fragments containing the target sequence can be tracked by the UMI, each plant from which the polynucleotide comes can be tracked by the sample tag, and each plant from which the seed comes can be tracked by the sample tag sequence.

[0094] The foregoing examples may include further multiplexing associated with hybridization. Hybridization reactions may be performed with a single or paired target separation probe, or multiplexing may be performed by performing individual reactions with multiple hybridization probes (e.g., 3 or more, 5 or more, 10 or more, 100 or more, or 1,000 or more target separation probes).

[0095] Reagent test kit

[0096] The present disclosure relates to a kit for performing the methods described herein. The kit may, for example, include any system for delivering materials or reagents to implement the methods described herein. In some embodiments, the kit may include a system that allows reaction reagents (e.g., probes, enzymes, adapters, primers, reaction reagents, surfaces in reaction vessels and / or appropriate containers) and / or support materials (e.g., written instructions for performing assays, processing instructions) to be stored, transported from one location or delivered to another location. For example, in some embodiments, the kit includes one or more housings (e.g., boxes) containing one or more reaction reagents and / or support materials. Such contents may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme for an enrichment method, and a second container may contain adapters. The kit in separate or combined form may be formulated for selecting and enriching a target template from a nucleic acid sample containing a non-target sequence and a target sequence. The kit may include one or more adapters as described herein; primers; exonucleases; ligases; polymerases (one or more); buffers; and nucleotides. The kit may also include one or more buffer solutions and standard solutions for creating a DNA library. The components may be present in a single reaction vessel or in multiple tubes and may be packaged individually or together.

[0097] Automated workflow

[0098] The methods disclosed herein can be performed with at least some automation. Systems for processing multiple samples in parallel can be adapted for use with the disclosed methods. For example, systems for processing samples in a rack, a multiwell plate, droplets on a surface, and / or through microfluidics (including the use of pressure, electric potential, acoustic force, and / or other forces to manipulate changes in fluids and contact materials). The methods disclosed herein can be performed, for example, using 525 Liquid Processor( 525 Liquid Handler) (Labcyte, Inc., San Jose, CA) or with the aid of a microfluidic device or a chip lab (Aqua Drop, Sharp). Figure 1A In the method shown in , steps 1010, 1020, and 1030 can be performed in a single buffer, which is then replaced with a different buffer in step 1040. Steps 1050-1090 can be performed in a single reaction tube by adding reagents sequentially or together. In some embodiments, the steps from sample to sequencing can be automated on a single device.

[0099] In some embodiments, it may be desirable to combine an enriched library with one or more other enriched libraries, e.g., for sequencing. For example, multiple environmental samples may be collected and enriched libraries may be prepared from each sample (e.g., enriched for possible pathogenic DNA present). This may be achieved in a platform employing, for example, a 96-well dish, where 5' adapter addition, hybridization, capture, enrichment, and 3' adapter addition are performed in a single well of the 96-well plate. After achieving 5' adapter fusion of polynucleotide fragments from a single sample (single environmental sample), polynucleotide fragments from multiple samples (samples from multiple locations or samples from a single location over time) from all 96 wells may be combined into a single well of a second 96-well plate for capture enrichment and 3' adapter fusion. Multiple samples (representing multiple samples) from multiple wells in the second plate may then be combined for sequencing. Sequence data may be deconvoluted using sample tags and / or UMIs to associate specific sequences with specific samples.

[0100] Example

[0101] Some specific example implementations may be illustrated by one or more of the examples provided herein.

[0102] Example 1: Library preparation including fragmentation and adaptor ligation

[0103] In some embodiments, the Figure 1A and Figure 1B The embodiment shown in the figure is used to practice the enrichment method. As shown, method 1000 can include fragmenting 1010 a polynucleotide (e.g., genomic DNA) to form fragmented polynucleotides. The fragmented polynucleotides can include hybridized positive 1011 strands and negative 1012 strands. Fragmentation 1010 can include physically, mechanically, chemically and / or enzymatically fragmenting the polynucleotides.

[0104] In some embodiments, a method may include preparing 1020 the ends of a fragmented polynucleotide for adapter ligation. Preparing 1020 the ends of a fragmented polynucleotide for adapter ligation may include (a) repairing 1020a the ends of the fragmented polynucleotide to form a blunt 5' end and a blunt 3' end, (b) adding an A tail 1020b to the 3' end, or (c) simultaneously (a) and (b) (e.g., sequentially) to form a single base A overhang at each 3' end. The prepared fragmented polynucleotide comprises a positive 1021 strand and a negative 1022 strand that are hybridized to each other, and comprises a blunt end or an A tailed end.

[0105] The method may include contacting 1030 (e.g., ligating) a fragmented polynucleotide having a 3' end with an A-tailed 5' nucleotide with a first adapter (e.g., a double-stranded adapter, a single-stranded hairpin adapter) having a blunt end or a 5' nucleotide complementary to the 3' A-tail. In some embodiments, the first adapter, adapter 1033, may include an upper strand 1034 and a lower strand 1035. The double-stranded adapter, in some embodiments, may include a plurality of deoxyuridines in the upper strand, in the lower strand, or in both the upper strand and the lower strand. The upper strand 1034 of adapter 1033 may include, in the 5' to 3' direction: a linear amplification annealing site ( Figure 1B LAAS in the fragmented polynucleotides); optionally a sample tag (e.g., i5); a unique molecular identifier (UMI); a sequence complementary to the lower strand 1034; and a nucleotide complementary to A. The lower strand 1035 of the adaptor 1033 may include: in the 5' to 3' direction: 5'-OH (e.g., a 5' end lacking a phosphate); a sequence complementary to the upper strand; and a non-extendable modified nucleotide (e.g., an inverted dT). Contacting 1030, in some embodiments, may include ligating the 3' end of the upper strand of the adaptor to the 5' end of the fragmented polynucleotide without ligating the 5' end of the lower strand of the adaptor to the 3' (A-tailed) end of the fragmented polynucleotide to form a double-stranded ligation product, the double-stranded ligation product including a plus strand 1031 comprising a single-strand break or nick and a minus strand 1032 comprising a single-strand break or nick.

[0106] According to some embodiments, method 1000 may include contacting 1040 the double-stranded ligation product comprising nicks 1046 and 1047 with a nick translation or strand displacement polymerase to form a nick translated duplex polynucleotide comprising a positive strand 1041 and a negative strand 1042. Examples of nick translation polymerases include E. coli DNA polymerase I, pol Ik, Taq DNA polymerase, DNA polymerase (New England Biolabs, Inc.), Bst DNA polymerase (eg, large fragment), Bsu DNA polymerase, phi29 DNA polymerase, Therminator TM DNA polymerase, Klenow, DNA polymerase and Deep DNA polymerase.

[0107] Method 1000 can include, in some embodiments, contacting 1050 a nick-translated duplex polynucleotide (e.g., comprising one or more modified nucleotides) with a single nucleotide excision reagent to form a polynucleotide duplex comprising a positive strand 1051 and a negative strand 1052, each of which comprises a gap (e.g., previously occupied by a modified nucleotide) defining an oligonucleotide of a different (e.g., typically short) length. For example, the positive strand 1051 of the formed polynucleotide duplex can comprise, in the 5' to 3' direction: a portion having a gap (e.g., a single nucleotide previously occupied by a U); a positive strand of a double-stranded fragmented polynucleotide; and a portion comprising a sequence complementary to a first adaptor, a UMI, a sample tag, and a linear amplification annealing site.

[0108] Examples of single nucleotide excision reagents may include enzyme preparations that effect uracil removal and phosphodiester bond cleavage (e.g., The method may include removing oligonucleotides formed by treating with a mononucleotide excision agent.

[0109] Method 1000 can include contacting 1060 each strand (1051, 1052) of the labeled fragments (polynucleotide duplexes comprising a double-stranded fragmented polynucleotide and a 3' overhang (e.g., a 3' overhang comprising, in the 5' to 3' direction: a sequence complementary to a first adaptor, a sample tag, a UMI, and a linear amplification annealing site)) with a linear amplification primer 1061 having a sequence complementary to the linear amplification annealing site to form annealed complexes 1065 and 1066. In some implementations, the method can include contacting 1070 the annealed complexes 1065 and 1066 with a polymerase to form a primer extension product 1071 complementary to the positive strand 1051 and a primer extension product 1072 complementary to the negative strand 1052. This annealing 1060 and primer extension 1070 can be repeated as needed (e.g., repeated for a total of 2 to 200 cycles) to amplify each strand (1051, 1052) of the polynucleotide duplex comprising the double-stranded fragmented polynucleotide and the 3' overhang, in which case the primer extension products can be collectively referred to as amplification products. The amplification here is linear because each strand of the polynucleotide duplex has only one linear annealing site. The resulting primer extension products constitute a linearly amplified polynucleotide population corresponding to the original fragmentation product. The primer extension products may include, in the 5' to 3' direction: a copy of the primer; a sample tag; a UMI; a sequence that is partially complementary to an adapter; and a copy of the positive strand of the double-stranded fragmented polynucleotide or a copy of the negative strand of the double-stranded fragmented polynucleotide. Method 1000 may optionally include merging 1075 primer extension products (e.g., primer extension products derived from a workflow that does not contain a previous merging step) after linear amplification.

[0110] In some embodiments, the primer extension product can be queried for the presence of a polynucleotide having a sequence of interest ("target sequence"). For example, the method can include contacting the primer extension product with a target separation probe (1081, 1082) 1080 to form a mixture comprising the primer extension product and the target separation probe. If the target sequence is present, the mixture can further include a target complex 1085, 1086, which includes a primer extension product having a target sequence that hybridizes (e.g., specifically hybridizes) with a target-specific oligonucleotide of the target separation probe. The target separation probe (bait) can include an affinity domain (e.g., biotin) and a polynucleotide having a polynucleotide sequence complementary to the positive strand of a sequence of interest (e.g., a sequence of interest at any position within a fragmented polynucleotide, e.g., at or near the 5' or 3' end of the positive strand of the fragmented polynucleotide) or a polynucleotide sequence complementary to the negative strand of a sequence of interest (e.g., a sequence of interest at any position within a fragmented polynucleotide, e.g., at or near the 5' or 3' end of the negative strand of the fragmented polynucleotide). The conditions of contacting 1080 can be adjusted as desired, for example, to increase or decrease the stringency of hybridization of the bait to the target sequence.

[0111] Optionally, method 1000 can include contacting 1090 the mixture potentially containing the target complex with a 3' single stranded exonuclease to remove any 3' overhang and form an end (eg, blunt end) defined by the 3' end of the target sequence and the 5' end of the bait.

[0112] In some embodiments, method 1000 can include contacting 1100 a mixture potentially containing target complexes 1085, 1086 with a solid support 1101 (e.g., magnetic beads) that contains an affinity capture domain (e.g., streptavidin) corresponding to the affinity domain (e.g., biotin) of the target separation probe. Contacting 1100 can include binding the affinity domain (e.g., biotin) to its corresponding affinity capture domain (e.g., streptavidin) to form an affinity capture complex 1105, the affinity capture complex 1105 containing the affinity domain bound to the affinity capture domain. Contacting 1100 can be performed to enrich for primer extension products having a target sequence. For example, if the affinity domain is biotin, the target sequence can be enriched by binding the affinity domain (biotin) to a support (e.g., beads) containing a streptavidin affinity capture domain. In some embodiments, streptavidin-coated magnetic beads can be added to the reaction mixture after the primer extension products are hybridized to the target-specific oligonucleotide.

[0113] In some embodiments, method 1000 can optionally include enriching 1110 affinity capture complexes 1105, for example, by securing the solid support with a magnet for magnetic beads, and / or washing to remove unbound affinity capture domains. The magnetic beads can be separated magnetically and then washed to enrich for complexes containing primer extension products having a target sequence.

[0114] Method 1000 may include contacting 1120 the blunt-ended target complex with a second adaptor (e.g., blunt-ended adaptor 1121). Blunt-ended adaptor 1121 may have an upper strand 1121a and a lower strand 1121b. Upper strand 1121a may include, in the 5'-3' direction: a 5' phosphate, a sequence complementary to the adaptor lower strand, and a nuclease-resistant 3' end. The blunt-ended adaptor nuclease-resistant 3' end may include one or more phosphorothioate internucleotide bonds and / or a 3' C3 spacer sequence (Integrated DNA Technologies, Inc.). Upper strand 1121a may optionally include a sample tag (optionally, the same or different from the sample tag of adaptor 1033). Blunt-ended adaptor lower strand 1121b may be shorter than the upper strand and include deoxyuridine without a 5' phosphate, no sample tag, no UMI, and no linear amplification annealing site. The blunt-ended adapter lower strand 1121b may comprise a sequence that is at least partially complementary to the 5' end of the upper strand 1121a. The contacting 1120 may further comprise contacting the blunt-ended target complex and the blunt-ended adapter 1121 with a ligase to form a target complex-adapter ligation product. The ligation product may be washed, for example, to remove unligated adapters from the target complex-adapter ligation product.

[0115] Method 1000 can include contacting 1130 the target complex-adapter ligation product with an amplification primer comprising, in the 5' to 3' direction: a sequence complementary to the blunt-ended adaptor and a sample tag shown as an index 1 (i7) sequence (optionally, the same or different from the sample tag of adaptor 1033). Contacting 1130 can further include amplification (e.g., by PCR, LAMP) to form a population of polynucleotides enriched for the target sequence (e.g., relative to the original fragmented polynucleotide population), which population can be referred to as a final amplified library. For example, the final amplified library can be sequenced using an available next-generation sequencing protocol (e.g., Illumina).

[0116] Example 2

[0117] In some embodiments, the Figure 2A and Figure 2BThe enrichment method can be practiced according to the embodiment shown. As shown, method 2000 can include attaching 2030 a polynucleotide (e.g., an unfragmented polynucleotide) to a first adaptor (e.g., a double-stranded adaptor, a single-stranded hairpin adaptor) (e.g., by bead-attached tagmentation or in-solution tagmentation). In some embodiments, the first adaptor, adaptor 2303, can include an upper strand 2034 and a lower strand 2035. The double-stranded adaptor, in some embodiments, can include a plurality of deoxyuridines in the upper strand, in the lower strand, or in both the upper strand and the lower strand. The upper strand 1034 of adaptor 2033 can include, in the 5' to 3' direction: a linear amplification annealing site ( Figure 2B LAAS in the fragmented polynucleotide); optionally a sample tag (e.g., i5); a unique molecular identifier (UMI); and a sequence complementary to the lower strand 2034 (e.g., including a transposase binding sequence). The lower strand 2035 of the adaptor 2033 may include, in the 5' to 3' direction: a 5'-OH (e.g., a 5' end lacking a phosphate); a sequence complementary to the upper strand; and a non-extendable modified nucleotide (e.g., an inverted dT). Contacting 2030, in some embodiments, may include connecting the 3' end of the upper strand of the adaptor to the 5' end of the fragmented polynucleotide without connecting the 5' end of the lower strand of the adaptor to the 3' end of the fragmented polynucleotide to form a double-stranded ligation product, the double-stranded ligation product including a positive strand 2031 including a single-strand break or nick and a negative strand 2032 including a single-strand break or nick.

[0118] According to some embodiments, method 2000 may include contacting 2040 the double-stranded ligation product comprising nicks 2046 and 2047 with a nick translation or strand displacement polymerase to form a nick translated duplex polynucleotide comprising a positive strand 2041 and a negative strand 2042. Examples of nick translation polymerases include E. coli DNA polymerase I, pol Ik, Taq DNA polymerase, DNA polymerase (New England Biolabs, Inc.), Bst DNA polymerase (eg, large fragment), Bsu DNA polymerase, phi29 DNA polymerase, Therminator TM DNA polymerase, Klenow, DNA polymerase and Deep DNA polymerase.

[0119] Method 2000 can include, in some embodiments, contacting 2050 a nick-translated duplex polynucleotide (e.g., comprising one or more modified nucleotides) with a single nucleotide excision reagent to form a polynucleotide duplex comprising a positive strand 2051 and a negative strand 2052, each of which comprises a gap (e.g., previously occupied by a modified nucleotide) defining an oligonucleotide of a different (e.g., typically short) length. For example, the positive strand 2051 of the formed polynucleotide duplex can comprise, in the 5' to 3' direction: a portion having a gap (e.g., a single nucleotide previously occupied by a U); a positive strand of a double-stranded fragmented polynucleotide; and a portion comprising a sequence complementary to a first adaptor, a UMI, a sample tag, and a linear amplification annealing site.

[0120] Examples of single nucleotide excision reagents may include enzyme preparations that effect uracil removal and phosphodiester bond cleavage (e.g., The method may include removing oligonucleotides formed by treating with a mononucleotide excision agent.

[0121] Method 2000 can include contacting 2060 each strand (1051, 2052) of the labeled fragments (polynucleotide duplexes comprising a double-stranded fragmented polynucleotide and a 3' overhang (e.g., a 3' overhang comprising, in the 5' to 3' direction: a sequence complementary to a first adaptor, a sample tag, a UMI, and a linear amplification annealing site)) with a linear amplification primer 2061 having a sequence complementary to the linear amplification annealing site to form annealed complexes 2065 and 2066. In some implementations, the method can include contacting 2070 the annealed complexes 2065 and 2066 with a polymerase to form a primer extension product 2071 complementary to the positive strand 2051 and a primer extension product 2072 complementary to the negative strand 2052. This annealing 2060 and primer extension 2070 can be repeated as needed (e.g., repeated for a total of 2 to 200 cycles) to amplify each strand (1051, 2052) of the polynucleotide duplex comprising the double-stranded fragmented polynucleotide and the 3' overhang, in which case the primer extension products can be collectively referred to as amplification products. The amplification here is linear because each strand of the polynucleotide duplex has only one linear annealing site. The resulting primer extension products constitute a linearly amplified polynucleotide population corresponding to the original fragmentation products. The primer extension products can include, in the 5' to 3' direction: a copy of the primer; a sample tag; a UMI; a sequence that is partially complementary to an adapter; and a copy of the positive strand of the double-stranded fragmented polynucleotide or a copy of the negative strand of the double-stranded fragmented polynucleotide. Method 2000 can optionally include merging 2075 primer extension products (e.g., primer extension products derived from a workflow that does not contain a previous merging step) after linear amplification.

[0122] In some embodiments, the primer extension product can be queried for the presence of a polynucleotide having a sequence of interest ("target sequence"). For example, the method can include contacting 2080 the primer extension product with a target separation probe (1081, 2082) to form a mixture comprising the primer extension product and the target separation probe. If the target sequence is present, the mixture can further include a target complex 2085, 2086, which includes a primer extension product having a target sequence that hybridizes (e.g., specifically hybridizes) with a target-specific oligonucleotide of the target separation probe. The target separation probe (bait) can include an affinity domain (e.g., biotin) and a polynucleotide having a polynucleotide sequence complementary to the positive strand of a sequence of interest (e.g., a sequence of interest at any position within a fragmented polynucleotide, e.g., at or near the 5' or 3' end of the positive strand of the fragmented polynucleotide) or a polynucleotide sequence complementary to the negative strand of a sequence of interest (e.g., a sequence of interest at any position within a fragmented polynucleotide, e.g., at or near the 5' or 3' end of the negative strand of the fragmented polynucleotide). The conditions of contacting 2080 can be adjusted as desired, for example, to increase or decrease the stringency of hybridization of the bait to the target sequence.

[0123] Optionally, method 2000 can include contacting 2090 the mixture potentially containing the target complex with a 3' single-stranded exonuclease to remove any 3' overhangs and form an end (eg, blunt end) defined by the 3' end of the target sequence and the 5' end of the bait.

[0124] In some embodiments, method 2000 can include contacting 2200 a mixture potentially containing target complexes 2085, 2086 with a solid support 2101 (e.g., magnetic beads) that contains an affinity capture domain (e.g., streptavidin) corresponding to the affinity domain (e.g., biotin) of the target separation probe. Contacting 2100 can include binding the affinity domain (e.g., biotin) to its corresponding affinity capture domain (e.g., streptavidin) to form an affinity capture complex 2105, the affinity capture complex 2105 containing the affinity domain bound to the affinity capture domain. Contacting 2100 can be performed to enrich for primer extension products having a target sequence. For example, if the affinity domain is biotin, the target sequence can be enriched by binding the affinity domain (biotin) to a support (e.g., beads) containing a streptavidin affinity capture domain. In some embodiments, streptavidin-coated magnetic beads can be added to the reaction mixture after the primer extension products are hybridized to the target-specific oligonucleotide.

[0125] In some embodiments, method 2000 can optionally include enriching 2110 affinity capture complexes 2105, for example, by capturing the solid support with a magnet for magnetic beads, and / or washing to remove unbound affinity capture domains. The magnetic beads can be separated magnetically and then washed to enrich for complexes containing primer extension products having a target sequence.

[0126] Method 2000 may include contacting 2120 the blunt-ended target complex with a second adaptor (e.g., blunt-ended adaptor 2121). The blunt-ended adaptor 2121 may have an upper strand 2121a and a lower strand 2121b. The upper strand 2121a may include, in the 5'-3' direction: a 5' phosphate, a sequence complementary to the adaptor lower strand, and a nuclease-resistant 3' end. The blunt-ended adaptor nuclease-resistant 3' end may include one or more phosphorothioate internucleotide bonds and / or a 3' C3 spacer sequence (Integrated DNA Technologies, Inc.). The upper strand 2121a may optionally include a sample tag (optionally, the same or different from the sample tag of the adaptor 2033). The blunt-ended adaptor lower strand 2121b may be shorter than the upper strand and include deoxyuridine without a 5' phosphate, no sample tag, no UMI, and no linear amplification annealing site. The blunt-ended adapter lower strand 2121b may comprise a sequence that is at least partially complementary to the 5' end of the upper strand 2121a. The contacting 2120 may further comprise contacting the blunt-ended target complex and the blunt-ended adapter 2121 with a ligase to form a target complex-adapter ligation product. The ligation product may be washed, for example, to remove unligated adapters from the target complex-adapter ligation product.

[0127] Method 2000 can include contacting 2130 the target complex-adapter ligation product with an amplification primer comprising, in the 5' to 3' direction: a sequence complementary to the blunt-ended adaptor and a sample tag shown as an index 1 (i7) sequence (optionally, the same or different from the sample tag of adaptor 2033). Contacting 2130 can further include amplification (e.g., by PCR, LAMP) to form a population of polynucleotides enriched for the target sequence (e.g., relative to the original fragmented polynucleotide population), which population can be referred to as a final amplified library. For example, the final amplified library can be sequenced using an available next-generation sequencing protocol (e.g., Illumina).

[0128] Example 3: Enrichment of library of target sequences from human DNA using linear amplification

[0129] Human gDNA was added to the NEBNext Ultra II End Repair / dA-Tailing enzyme mix and buffer according to the manufacturer's instructions (NEB). The mixture was cooled to 4°C and double-stranded adapter template (first adapter) was added, with the top strand being 5'A*A*T*GAU ACG GCG ACC ACC GAG AUCUAC ACT ATA GCC TNN NNN NNN NNN N AC ACU CTT TCC CUA CAC GAC GCU CTT CCG AUC*T (SEQ ID NO: 1), where the asterisk indicates a phosphorothioate linkage and the bold underlined text indicates an example sample label.

[0130] There are 12N (random sequence of 12 nucleotides) UMI, sample tag (8 bold underlined letters) and several deoxyuridine residues in the adapter. Add NEBNext Ultra II ligation master mix to the reaction mixture and incubate at 20°C for 15 minutes, followed by incubation at 65°C for 15 minutes. Add nick translation polymerase and dNTPs and incubate at 65°C for another 45 minutes, followed by incubation at 80°C for 20 minutes. After cooling to room temperature, add USER enzyme, followed by incubation at 37°C for 15 minutes. Purify DNA fragments using NEB sample purification beads and elute in nuclease-free water.

[0131] DNA fragments in water were added to NEBNext Hot Start HiFi 2X Master Mix and a linear amplification primer with the sequence 5'AATGATACGGCGACCACC 3' (SEQ ID NO: 2), in which the 3'OH was replaced by a 3'C3 spacer sequence (Integrated DNA Technologies, Inc.). The reaction was incubated at 98°C for 30 seconds, followed by 20 cycles of 98°C for 10 seconds, 55°C for 45 seconds, 72°C for 20 seconds, and a final incubation at 72°C for 5 minutes ( Figure 1A-1B Step 3).

[0132] This reaction was transferred to a hybridization mix containing target breakaway probes, each of which contained a target-specific oligonucleotide (bait) and an affinity domain (i.e., biotin), and incubated at 95 °C for 10 min and then at 58 °C for 16 h ( Figure 1A-1B Step 4). A target-specific oligonucleotide was designed to bind to the 3' end of the target region. After hybridization, the target isolation probe / target DNA complex was allowed to bind to NEB hydrophilic streptavidin magnetic beads at 48°C for 10 minutes and then washed twice with wash buffer at 62°C for 5 minutes ( Figure 1A-1B Step 5).

[0133] The beads were resuspended in 3'-5' single-stranded exonuclease buffer containing enzyme and incubated at 25°C for 10 min and at 37°C for 5 min ( Figure 1A-1B The beads were then washed and resuspended in 1x NEB Quick Ligation Buffer. NEB Quick Ligase and the 3' adapter to be ligated to the 3' end of the target sequence were added to the buffer and incubated at 20°C for 15 minutes ( Figure 1A-1B Step 6). This 3' adapter has protective modifications at the 3' end of the upper strand and the complementary lower strand, containing modified bases. The upper strand sequence of the 3' adapter is 5'5Phos / AGATC GGAAG AGCAC ACGTC TGAAC TCC*A*G*T*C*A*C / 3SpC3 3' (SEQ ID NO: 3), and the lower strand sequence is 5'ACGNG TGCNC TNCCG ANC*T 3', where N is ideoxyU (SEQ ID NO: 4). The beads were then washed and resuspended in 100 μl of 1xNEBuffer 1 containing endonuclease VIII and UDG, and incubated at 37°C for 15 minutes ( Figure 1A-1B of 1090).

[0134] The beads were then washed and resuspended in NEBNext PCR primers were added to 1x NEBNext Q5 Hot Start HiFi PCR Master Mix (New England Biolabs, Ipswich, MA) for PCR amplification.

[0135] Example 4: Analysis of enriched libraries

[0136] According to Example 1, starting with 15, 30 and 100 ng of fragmented human DNA input, enriched libraries were prepared and sequenced with paired end reads of 75 bp. The original sequencing file was demultiplexed using the Picard tool Extract Illumina Barcodes to assign the reads to the sample index, and then an unmapped BAM file was created with Picard's Illumina Basecalls To Sam, which contains the reads of each sample ("Picard Toolkit" 2019, Broad Institute, GitHub Repository). Unaligned BAM was aligned with the human reference genome (GRCh38 / hg38 version) using bwa mem (Li H., 2013, Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.arXiv:1303.3997v2[q-bio.GN]). Picard's MarkDuplicates was then used to identify sequencing duplicates using both position and unique molecular indexes (UMIs). Duplicates marked with BAM were then used for variant calling.GATK's HaplotypeCaller was used for germline calling, and both GATK's MuTect2 and AstraZeneca's VarDict were used for somatic calling (Poplin R, et al., 2017, Scaling accurate genetic variant discovery to tens of thousands of samples bioRxiv, 201178. DOI: 10.1101 / 201178; "GATK Mutect2" 2019, Broad Institute, GitHub Repository; David Benjamin et al., 2019, Calling Somatic SNVs and Indels with Mutect2. bioRxiv 861054; doi: https: / / doi.org / 10.1101 / 861054; Zhongwu Lai et al., VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research, Nucleic Acids Research, Volume 44, Issue 11, June 20, 2016, Page 108, https: / / doi.org / 10.1093 / nar / gkw227). QC metrics were calculated from BAM-labeled replicates using a combination of Picard and custom tools. Figure 3A (75kb target), Figure 3B (227kb target) and Figure 3C The sequencing depth covering the number of reads for all these target enriched libraries is shown in (1100 kb target).

Claims

1. A method comprising: (a) fusing a DNA adaptor to the 5' end of a double-stranded polynucleotide fragment of a fragment population, wherein the DNA adaptor comprises a bottom strand and an top strand, wherein: (i) the upper strand of the adaptor comprises, from 5' to 3': A sequence of at least 8 nucleotides complementary to the linear amplification annealing site, Optionally, a sample label, Optionally, a unique molecular identifier (UMI); and a sequence complementary to the bottom strand of the adaptor; and (ii) the bottom strand of the adaptor comprises a non-extendable 3' end, wherein one or more of the polynucleotide fragments comprises a target sequence and wherein a fusion product is formed comprising the 3' end of the upper strand of the adaptor fused to the 5' end of the polynucleotide fragment and a nick comprising the unfused 5' end of the lower strand of the adaptor and the 3' end of the polynucleotide fragment; (b) contacting the fusion product with a nick translation polymerase for templated addition of nucleotides to the 3' end of the polynucleotide fragment to form a nick translation product comprising a 3' extension of the polynucleotide fragment, the extension being complementary to the upper strand of the adaptor; and (c) contacting the nick translation product with a primer having a sequence complementary to the linear amplification annealing site and a polymerase to produce a linear amplified nick translation product, the linear amplified nick translation product comprising, in the 5' to 3' direction: A sequence complementary to the linear amplification annealing site, Optionally, the sequence of the sample tag, Optionally, the sequence of the UMI, the sequence of the upper strand portion of the adaptor, a sequence of one of the polynucleotide fragments, and Optionally, a sequence that is complementary to a portion of the bottom strand of the adaptor.

2. The method of claim 1, further comprising, before or simultaneously with (c), contacting the nick translation product with a glycosylase and an endonuclease, wherein the adapter upper strand template further comprises one or more modified nucleotides, wherein the one or more modified nucleotides are optionally deoxyuridine, the glycosylase is optionally uracil-DNA glycosylase (UDG), and the endonuclease is optionally endonuclease VIII.

3. The method according to claim 1 or 2, further comprising, after (1b), removing the adapter lower strand by cutting the adapter lower strand of the adapter template with a reagent comprising a glycosylase and an endonuclease, wherein the adapter lower strand comprises one or more modified nucleotides, wherein the one or more modified nucleotides are optionally deoxyuridine, the glycosylase is optionally uracil-DNA glycosylase (UDG), and the endonuclease is optionally endonuclease VIII.

4. The method of any one of claims 1-3, wherein the non-extendable 3' end of the lower strand of the adaptor comprises an inverted deoxythymidine.

5. The method according to claim 1 or 2, further comprising: (d) contacting the linearly amplified nick translation product with a target-specific oligonucleotide attached to an affinity domain to form a target complex, the target complex comprising a polynucleotide fragment having the target sequence, the target-specific oligonucleotide, and the affinity domain, wherein the target sequence is hybridized to the target-specific oligonucleotide.

6. The method according to claim 5, further comprising: (e) binding the target complex to a solid support comprising an affinity capture domain corresponding to the affinity domain.

7. The method of claim 6, wherein the affinity domain is biotin and the affinity capture domain comprises streptavidin.

8. The method according to claim 5 or claim 6, further comprising: (f) removing any overhanging polynucleotide sequence at the 3' end of the oligonucleotide hybridized complementary strand using a 3'-5' single-stranded exonuclease or multiple 3'-5' exonucleases to form a blunt-ended duplex of the 3' end of the complementary sequence and the 5' end of the oligonucleotide; (g) fusing the blunt-ended duplex to a second adaptor comprising a second sample tag to form a second fusion product, the second fusion product comprising, in the 5' to 3' direction: the upper strand of the first adaptor, the oligonucleotide fragment, and the second adaptor; and (h) amplifying the second fusion product to sequence one or both of the strands.

9. The method according to claim 1, further comprising: The nick translation product is combined with further nick translation products, each of which comprises, in the 5' to 3' direction: A sequence complementary to the linear amplification annealing site, Further sample tag sequences, Optionally, the sequence of the UMI, further the sequence of the upper strand portion of the adaptor, and Further the sequences of the polynucleotide fragments of the population of fragments.

10. The method according to claim 1, further comprising: Repeating step (a) with a second DNA adaptor and double-stranded polynucleotide fragments of a second fragment population, wherein the first adaptor top strand comprises a sample tag, and wherein the second adaptor comprises a bottom strand and a top strand, wherein (i) the second adaptor upper strand comprises, from 5' to 3': a sequence of at least 8 nucleotides complementary to the linear amplification annealing site, a sample tag different from said first adaptor sample tag, Optionally, a unique molecular identifier (UMI); and a sequence complementary to the bottom strand of the second adaptor; and (ii) the second adaptor bottom strand comprises a non-extendable 3' end, wherein one or more of the polynucleotide fragments of the second population comprises a target sequence and wherein further fusion products are formed, the further fusion products comprising the 3' end of the second adaptor upper strand fused to the 5' end of the polynucleotide fragments of the second population and a nick comprising the unfused 5' end of the second adaptor lower strand and the 3' end of the polynucleotide fragments of the second population; and The fusion product is combined with the further fusion product to form a combined fusion product.

11. The method according to claim 10, wherein contacting the fusion products with the nick translation polymerase further comprises contacting the combined fusion products with the nick translation polymerase to template-add nucleotides to the 3' ends of the polynucleotide fragments to form combined nick translation products comprising 3' extensions of the polynucleotide fragments, the extensions being complementary to the corresponding adaptor top strands; and wherein contacting the nick translation products with a primer having a sequence complementary to the linear amplification annealing site further comprises contacting the combined nick translation products with the primer and the polymerase to produce linearly amplified combined nick translation products, the linearly amplified combined nick translation products comprising, in the 5' to 3' direction: A sequence complementary to the linear amplification annealing site, The sequence of one of the corresponding sample tags, Optionally, the sequence of the UMI, The sequence of the portion of the upper strand of the corresponding adaptor, a sequence of one of the polynucleotide fragments, and Optionally, a sequence that is complementary to a portion of the bottom strand of the corresponding adaptor.

12. The method according to any preceding claim, wherein the fusing of step (a) comprises ligating or tagging the DNA adaptor to the 5' end of the double-stranded polynucleotide fragment.

13. The method of any preceding claim, wherein the top strand is longer than the adaptor bottom strand.

14. The method of claim 13, wherein the adapter upper strand comprises at least one of an optional sample tag and an optional UMI.

15. The method of claim 13 or 14, wherein the adapter bottom strand contains no 5' phosphate, no sample tag, no UMI, and no linear amplification annealing site.

16. A method for enriching a target sequence, the method comprising: (a) contacting a population of fragmented polynucleotides with a ligase and a first adaptor, wherein the first adaptor comprises a lower strand and a longer upper strand, wherein (i) the bottom strand comprises, in the 5' to 3' direction: 5'-OH; at least 10 nucleotides complementary to the top strand; and Optionally, reverse dT; and (ii) the top strand comprises, in the 5' to 3' direction: a sequence complementary to a linear amplification annealing site; optionally, a sample tag; a unique molecular identifier (UMI); and a sequence complementary to the bottom strand, wherein the top strand and the bottom strand optionally and independently comprise one or more deoxyuridines, and wherein (a) contacting produces a double-stranded fusion product comprising the 3' end of the top strand of the adaptor fused to the 5' end of the polynucleotide fragment and a nick comprising the unfused 5' end of the bottom strand of the adaptor and the 3' end of the polynucleotide fragment; (b) contacting the double-stranded fusion product with a nick translation polymerase and nucleotide triphosphates to form a nick translated duplex polynucleotide, wherein the duplex comprises: an upper strand comprising, in the 5' to 3' direction: the adaptor upper strand, the plus strand of one of the polynucleotide fragments, and a sequence complementary to the adaptor upper strand; and a lower strand comprising, in the 5' to 3' direction: the adaptor upper strand, the minus strand of one of the polynucleotide fragments, and a sequence complementary to the adaptor upper strand; (c) optionally contacting the nick translated duplex polynucleotide with a single nucleotide excision reagent to form a polynucleotide duplex comprising a plus strand and a minus strand, each of which comprises a single nucleotide gap in the adaptor upper strand of the nick translated duplex polynucleotide, the gap defining oligonucleotides of different lengths; (d) contacting the nick translated duplex polynucleotide with a linear amplification primer having a sequence complementary to the linear amplification annealing site to form an annealed duplex; (e) contacting the annealed duplex with a polymerase to form a primer extension product, the primer extension product comprising, In the 5' to 3' direction: a sequence corresponding to at least a portion of the upper strand of the adaptor, and a sequence corresponding to at least a portion of a positive strand of one of the polynucleotide fragments; (f) repeating the contacting under (d) and the contacting under (e) at least once; (g) contacting the primer extension product with a target separation probe comprising an affinity domain and a target-specific oligonucleotide to form a target probe mixture, the target probe mixture comprising: the primer extension product; Target separation probe; and, if one or more target sequences are present in the population of fragmented polynucleotides, a target complex comprising a primer extension product having a target sequence that is hybridized to a target-specific oligonucleotide of the target isolation probe; (h) contacting the target probe mixture with a solid support comprising an affinity capture domain to form an affinity complex comprising an affinity domain bound to an affinity capture domain, the affinity capture domain corresponding to the affinity domain of the target separation probe; and (i) separating the affinity complex from unbound primer extension products and unbound target separation probes to form an enriched target sequence composition.

17. The method of claim 16, wherein the adaptor top strand and the adaptor bottom strand each comprise a plurality of deoxyuridines, and the single nucleotide excision reagent removes deoxyuridines.

18. The method of claim 16, further comprising, prior to (a) contacting, A-tailing the fragmented polynucleotides, and wherein the top strand of the adaptor further comprises 3'T or dU.

19. The method of claim 16, wherein the first adaptor comprises the optional sample tag.

20. The method of claim 19, further comprising repeating steps (a) to (i), wherein the fragmented polynucleotide population of each repeated step (a) is different from all previous executions of step (a), and wherein the optional sample label of each repeated step (a) is different from all previous executions of step (a).

21. The method of claim 20, further comprising combining the affinity complexes produced by a first performance of steps (a) to (i) with the affinity complexes produced by each repetition of steps (a) to (i).

22. The method according to any one of claims 16-21, wherein the fusion of step (a) comprises ligation or tagging.

23. A method comprising: (a) fusing DNA adaptors to the 5' ends of double-stranded polynucleotide fragments of the fragment population, wherein the DNA adaptors comprise an upper strand and optionally a lower strand, wherein the adaptor upper strand comprises, from 5' to 3': A sequence of at least 8 nucleotides complementary to the linear amplification annealing site, Optionally, a sample label, Optionally, a unique molecular identifier (UMI); and Optionally, a sequence complementary to the bottom strand of the adaptor; and wherein one or more of the polynucleotide fragments comprises a target sequence and wherein a fusion product is formed comprising the 3' end of the adaptor upper strand fused to the 5' end of the polynucleotide fragment and a nick comprising the 3' end of the polynucleotide fragment and optionally the unfused 5' end of the adaptor lower strand; (b) contacting the fusion product with a nick translation polymerase for templated addition of nucleotides to the 3' end of the polynucleotide fragment to form a nick translation product comprising a 3' extension of the polynucleotide fragment, the extension being complementary to the upper strand of the adaptor; and (c) contacting the nick translation product with a primer having a sequence complementary to the linear amplification annealing site and a polymerase to produce a linear amplified nick translation product comprising, in the 5' to 3' direction: A sequence complementary to the linear amplification annealing site, Optionally, the sequence of the sample tag, Optionally, the sequence of the UMI, the sequence of the upper strand portion of the adaptor, a sequence of one of the polynucleotide fragments, and Optionally, a sequence that is complementary to a portion of the bottom strand of the adaptor.

24. The method of claim 23, wherein the adapter upper strand lacks a UMI and the DNA adapter lacks a lower strand.